PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 33720069-5 2021 In human epidermal growth factor receptor 2 (HER2)-positive oesophago-gastric adenocarcinoma, a phase II trial showed improved DFS when pertuzumab and trastuzumab were added to perioperative FLOT (5-fluorouracil/leucovorin, oxaliplatin, docetaxel). Docetaxel 237-246 erb-b2 receptor tyrosine kinase 2 Homo sapiens 45-49 33216943-1 2021 Pertuzumab and trastuzumab are monoclonal antibody inhibitors targeting human epidermal growth factor receptor 2 (HER-2) and are increasingly being utilised in the management of HER2-positive breast cancer, having been demonstrated to improve progression-free survival in conjunction with docetaxel. Docetaxel 289-298 erb-b2 receptor tyrosine kinase 2 Homo sapiens 114-119 33748921-0 2021 Subcutaneous trastuzumab with pertuzumab and docetaxel in HER2-positive metastatic breast cancer: Final analysis of MetaPHER, a phase IIIb single-arm safety study. Docetaxel 45-54 erb-b2 receptor tyrosine kinase 2 Homo sapiens 58-62 33748921-1 2021 PURPOSE: Intravenous trastuzumab, pertuzumab, and docetaxel are first-line standard of care for patients with HER2-positive metastatic breast cancer (mBC). Docetaxel 50-59 erb-b2 receptor tyrosine kinase 2 Homo sapiens 110-114 33685057-0 2021 [Docetaxel, carboplatin plus trastuzumab as neoadjuvant setting in patients with early-stage human epidermal growth factor receptor 2 positive breast cancer: a retrospective analysis]. Docetaxel 1-10 erb-b2 receptor tyrosine kinase 2 Homo sapiens 99-133 33685057-1 2021 Objective: To examine the efficacy of docetaxel, carboplatin plus trastuzumab regimen (TCH) as neoadjuvant setting in early-stage human epidermal growth factor receptor 2 (HER2) positive breast cancer. Docetaxel 38-47 erb-b2 receptor tyrosine kinase 2 Homo sapiens 136-170 33685057-1 2021 Objective: To examine the efficacy of docetaxel, carboplatin plus trastuzumab regimen (TCH) as neoadjuvant setting in early-stage human epidermal growth factor receptor 2 (HER2) positive breast cancer. Docetaxel 38-47 erb-b2 receptor tyrosine kinase 2 Homo sapiens 172-176 33716633-0 2021 Trastuzumab, Pertuzumab, and Docetaxel as the First Line for HER-2-Positive Metastatic Breast Cancer among Arabs. Docetaxel 29-38 erb-b2 receptor tyrosine kinase 2 Homo sapiens 61-66 33716633-3 2021 Patients and Methods: We identified 75 patients at King Faisal Specialist Hospital and Research Center that received trastuzumab, pertuzumab, and docetaxel as a first-line therapy in HER-2 positive MBC in 2013-2016. Docetaxel 146-155 erb-b2 receptor tyrosine kinase 2 Homo sapiens 183-188 33716633-10 2021 Conclusions: First line pertuzumab, trastuzumab, and docetaxel for HER-2-positive MBC patients was found to be an effective and safe therapy in the Saudi population. Docetaxel 53-62 erb-b2 receptor tyrosine kinase 2 Homo sapiens 67-72 34053967-2 2021 We conducted this phase II study to assess whether trastuzumab plus docetaxel was effective for patients with previously treated advanced HER2-positive gastric cancer. Docetaxel 68-77 erb-b2 receptor tyrosine kinase 2 Homo sapiens 138-142 33483889-1 2021 OBJECTIVE: The purpose of this analysis was to evaluate the cost effectiveness of the combination of pertuzumab, trastuzumab, and docetaxel (PTD) for the treatment of patients with human epidermal growth factor receptor-2 (HER2)-positive breast cancer in Japan. Docetaxel 130-139 erb-b2 receptor tyrosine kinase 2 Homo sapiens 187-221 33483889-1 2021 OBJECTIVE: The purpose of this analysis was to evaluate the cost effectiveness of the combination of pertuzumab, trastuzumab, and docetaxel (PTD) for the treatment of patients with human epidermal growth factor receptor-2 (HER2)-positive breast cancer in Japan. Docetaxel 130-139 erb-b2 receptor tyrosine kinase 2 Homo sapiens 223-227 33299647-6 2020 ERalpha+/HER2- cells with intermediate CIN were sensitive to treatment with taxanes (DOC) and anthracyclines (DOX), while ERalpha-/HER2-, ERalpha+/HER2+, and ERalpha-/HER2+ cells with intermediate CIN were resistant to these treatments. Docetaxel 85-88 erb-b2 receptor tyrosine kinase 2 Homo sapiens 9-13 33425535-2 2020 We present two cases of estrogen receptor-positive/progesterone receptor-positive/human epidermal growth factor receptor 2-positive (ER+/PR+/HER2+) breast cancer patients, treated with a non-anthracycline, non-alkylating regimen of trastuzumab, carboplatin, docetaxel, and pertuzumab (TCHP), who developed therapy-related acute myeloid leukemia (t-AML) within 30 months of the completion of treatment. Docetaxel 258-267 erb-b2 receptor tyrosine kinase 2 Homo sapiens 141-145 33468917-1 2020 Pertuzumab plus trastuzumab plus docetaxel regimen is the first choice for the initial treatment of HER2-positive recurrent breast cancer. Docetaxel 33-42 erb-b2 receptor tyrosine kinase 2 Homo sapiens 100-104 33046356-0 2020 Response and Prognosis of Docetaxel and Cyclophosphamide as Neoadjuvant Chemotherapy in ER+ HER2- Breast Cancer: A Prospective Phase II Study. Docetaxel 26-35 erb-b2 receptor tyrosine kinase 2 Homo sapiens 92-96 33205032-1 2020 Background: The open-label, randomised Phase 2 AVATAXHER study (NCT01142778) demonstrated that early PET assessment identified HER2-positive breast cancer patients who responded poorly to neoadjuvant docetaxel plus trastuzumab. Docetaxel 200-209 erb-b2 receptor tyrosine kinase 2 Homo sapiens 127-131 32439744-1 2020 We report the case of a 76-year-old female patient with early breast cancer (hormone receptor-positive erbb2 amplified) that had started adjuvant chemotherapy with docetaxel, carboplatin and trastuzumab (TCH). Docetaxel 164-173 erb-b2 receptor tyrosine kinase 2 Homo sapiens 103-108 32779037-1 2020 PURPOSE: Trastuzumab, pertuzumab, and docetaxel are the standard first-line therapy for HER2-positive (HER2+) metastatic breast cancer (MBC). Docetaxel 38-47 erb-b2 receptor tyrosine kinase 2 Homo sapiens 88-92 32779037-1 2020 PURPOSE: Trastuzumab, pertuzumab, and docetaxel are the standard first-line therapy for HER2-positive (HER2+) metastatic breast cancer (MBC). Docetaxel 38-47 erb-b2 receptor tyrosine kinase 2 Homo sapiens 103-107 33099918-1 2020 PURPOSE: To explore the efficacy and safety of bevacizumab combined with docetaxel in the treatment of human epidermal growth factor receptor-2 (HER-2)-negative recurrent metastatic breast cancer. Docetaxel 73-82 erb-b2 receptor tyrosine kinase 2 Homo sapiens 109-143 33099918-1 2020 PURPOSE: To explore the efficacy and safety of bevacizumab combined with docetaxel in the treatment of human epidermal growth factor receptor-2 (HER-2)-negative recurrent metastatic breast cancer. Docetaxel 73-82 erb-b2 receptor tyrosine kinase 2 Homo sapiens 145-150 33099918-12 2020 CONCLUSIONS: Bevacizumab combined with docetaxel has more excellent efficacy than docetaxel alone in the treatment of HER-2-negative recurrent metastatic breast cancer, and it prolongs the survival of patients, with tolerable adverse reactions, which is worthy of further clinical application. Docetaxel 39-48 erb-b2 receptor tyrosine kinase 2 Homo sapiens 118-123 33130751-0 2020 [Two Cases of Advanced HER2-Positive Locally Advanced Breast Cancer for Which Preoperative Chemotherapy with Pertuzumab, Trastuzumab, and Docetaxel Resulted in Good Response]. Docetaxel 138-147 erb-b2 receptor tyrosine kinase 2 Homo sapiens 23-27 33130751-9 2020 Combination therapy with pertuzumab, trastuzumab, and docetaxel appears to be a useful preoperative chemotherapy regimen for locally advanced HER2-positive breast cancer. Docetaxel 54-63 erb-b2 receptor tyrosine kinase 2 Homo sapiens 142-146 32850425-2 2020 9-month median overall survival with the triplet regimens of tucatinib, capecitabine, and trastuzumab (TXT) for patients with human epidermal growth factor receptor 2 (HER2) -overexpressing metastatic breast cancer. Docetaxel 103-106 erb-b2 receptor tyrosine kinase 2 Homo sapiens 132-166 32850425-2 2020 9-month median overall survival with the triplet regimens of tucatinib, capecitabine, and trastuzumab (TXT) for patients with human epidermal growth factor receptor 2 (HER2) -overexpressing metastatic breast cancer. Docetaxel 103-106 erb-b2 receptor tyrosine kinase 2 Homo sapiens 168-172 32504284-0 2020 N083E (Alliance): long-term outcomes of patients treated in a pilot phase II study of docetaxel, carboplatin, trastuzumab, and lapatinib as adjuvant therapy for early-stage HER2-positive breast cancer. Docetaxel 86-95 erb-b2 receptor tyrosine kinase 2 Homo sapiens 173-177 32171426-26 2020 HER2-targeted therapy has changed the natural history of HER2-positive metastatic breast cancer, with the dual blockade of pertuzumab and trastuzumab, with docetaxel, demonstrating an 8-year landmark overall survival rate of 37%. Docetaxel 156-165 erb-b2 receptor tyrosine kinase 2 Homo sapiens 0-4 32171426-0 2020 Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA): end-of-study results from a double-blind, randomised, placebo-controlled, phase 3 study. Docetaxel 29-38 erb-b2 receptor tyrosine kinase 2 Homo sapiens 43-47 32241871-0 2020 Preclinical Activity of HER2-Selective Tyrosine Kinase Inhibitor Tucatinib as a Single Agent or in Combination with Trastuzumab or Docetaxel in Solid Tumor Models. Docetaxel 131-140 erb-b2 receptor tyrosine kinase 2 Homo sapiens 24-28 31647503-13 2020 Conclusions and Relevance: Treatment with pertuzumab, trastuzumab, and docetaxel resulted in a statistically significant improvement in the total pathologic complete response rate vs placebo, trastuzumab, and docetaxel for the neoadjuvant treatment of ERBB2-positive early or locally advanced breast cancer in Asian patients. Docetaxel 71-80 erb-b2 receptor tyrosine kinase 2 Homo sapiens 252-257 31482205-2 2019 In the present study, we developed and synthesised two PAMAM dendrimer-trastuzumab conjugates that carried docetaxel or paclitaxel, specifically targeted to cells which overexpressed HER-2. Docetaxel 107-116 erb-b2 receptor tyrosine kinase 2 Homo sapiens 183-188 32194757-0 2020 Efficacy analysis of trastuzumab, carboplatin and docetaxel in HER-2-positive breast cancer patients. Docetaxel 50-59 erb-b2 receptor tyrosine kinase 2 Homo sapiens 63-68 32194757-1 2020 Efficacy of trastuzumab, carboplatin and docetaxel in human epidermal growth factor receptor-2 (HER-2)-positive breast cancer patients was investigated. Docetaxel 41-50 erb-b2 receptor tyrosine kinase 2 Homo sapiens 60-94 32194757-10 2020 In conclusion, trastuzumab, carboplatin and docetaxel present high efficacy, safety, and 5-year DFS and OS in HER-2-positive breast cancer patients, and have good recovery effect on inflammation, immune response and oxidative stress. Docetaxel 44-53 erb-b2 receptor tyrosine kinase 2 Homo sapiens 110-115 31805500-11 2020 CONCLUSIONS: From the perspective of the TNHIA, trastuzumab plus docetaxel as 1st line followed by T-DM1 and trastuzumab plus lapatinib as 2nd and 3rd line represents the most cost-effective strategy among the four sequences considered for treating HER-2-positive mBC patients. Docetaxel 65-74 erb-b2 receptor tyrosine kinase 2 Homo sapiens 249-254 32211111-1 2020 This study aimed to determine the correlation of human epidermal growth factor receptor 2 (HER2) codon 655 A>G polymorphism with cardiotoxicity risk in HER2-positive breast cancer patients undergoing epirubicin/cyclophosphamide followed by docetaxel plus trastuzumab (EC-D-T) adjuvant chemotherapy. Docetaxel 240-249 erb-b2 receptor tyrosine kinase 2 Homo sapiens 55-89 32211111-1 2020 This study aimed to determine the correlation of human epidermal growth factor receptor 2 (HER2) codon 655 A>G polymorphism with cardiotoxicity risk in HER2-positive breast cancer patients undergoing epirubicin/cyclophosphamide followed by docetaxel plus trastuzumab (EC-D-T) adjuvant chemotherapy. Docetaxel 240-249 erb-b2 receptor tyrosine kinase 2 Homo sapiens 91-95 31625523-7 2019 The results showed no cytotoxicity for the polymer, but the significant increment of cytotoxicity was observed by treatment with docetaxel-loaded NPs in both HER-2-positive and HER-2-negative cell lines, in comparison with the free drug. Docetaxel 129-138 erb-b2 receptor tyrosine kinase 2 Homo sapiens 158-163 31625523-7 2019 The results showed no cytotoxicity for the polymer, but the significant increment of cytotoxicity was observed by treatment with docetaxel-loaded NPs in both HER-2-positive and HER-2-negative cell lines, in comparison with the free drug. Docetaxel 129-138 erb-b2 receptor tyrosine kinase 2 Homo sapiens 177-182 31470686-3 2019 For this purpose, the impact on the level of reactive oxygen species, the mitochondrial membrane potential, cell cycle distribution and the activity of caspases-3/7, -8 and -9 of PAMAM-doc-trastuzumab and PAMAM-ptx-trastuzumab conjugates was determined and compared with free docetaxel and paclitaxel toward HER-2-positive (SKBR-3) and negative (MCF-7) human breast cancer cell lines. Docetaxel 185-188 erb-b2 receptor tyrosine kinase 2 Homo sapiens 308-313 31568001-0 2019 Clinical efficacy of combination of pertuzumab, trastuzumab, and docetaxel for treatment of patients with HER2-positive breast cancer. Docetaxel 65-74 erb-b2 receptor tyrosine kinase 2 Homo sapiens 106-110 31568001-1 2019 BACKGROUND: This study will systematically investigate the efficacy and safety of the combination of pertuzumab, trastuzumab, and docetaxel (PTD) for treatment of patients with HER2-positive breast cancer (HER2-PBC). Docetaxel 130-139 erb-b2 receptor tyrosine kinase 2 Homo sapiens 177-181 31470686-2 2019 For this reason, it is interesting to identify mechanisms of antitumor activity of PAMAM dendrimer conjugates that carry docetaxel or paclitaxel and monoclonal antibody trastuzumab, specifically targeted to cells which overexpressed HER-2. Docetaxel 121-130 erb-b2 receptor tyrosine kinase 2 Homo sapiens 233-238 30452336-0 2019 Phase II Trial of Trastuzumab and Docetaxel in Patients With Human Epidermal Growth Factor Receptor 2-Positive Salivary Duct Carcinoma. Docetaxel 34-43 erb-b2 receptor tyrosine kinase 2 Homo sapiens 61-101 31171748-0 2019 HER-2 aptamer-targeted Ecoflex nanoparticles loaded with docetaxel promote breast cancer cells apoptosis and anti-metastatic effect. Docetaxel 58-67 erb-b2 receptor tyrosine kinase 2 Homo sapiens 0-5 31508358-2 2019 Prognostic models for HER2-positive ABC patients considering first-line pertuzumab, trastuzumab, and docetaxel have not been evaluated. Docetaxel 101-110 erb-b2 receptor tyrosine kinase 2 Homo sapiens 22-26 31508358-9 2019 Conclusions: Pre-treatment prognostic groups identified for HER2-positive ABC patients initiating first-line pertuzumab, trastuzumab, and docetaxel had significantly different long-term disease control and survival outcomes. Docetaxel 138-147 erb-b2 receptor tyrosine kinase 2 Homo sapiens 60-64 30744691-6 2019 In in vivo experiment, we confirmed how DOC enhanced the recruitment of HER2-CAR T cells to tumor sites. Docetaxel 40-43 erb-b2 receptor tyrosine kinase 2 Homo sapiens 72-76 30452336-2 2019 We assessed the efficacy and toxicity of trastuzumab plus docetaxel in patients with locally advanced and/or recurrent or metastatic human epidermal growth factor receptor 2-positive SDC. Docetaxel 58-67 erb-b2 receptor tyrosine kinase 2 Homo sapiens 139-173 30452336-16 2019 CONCLUSION: Our data show encouraging efficacy of trastuzumab plus docetaxel therapy in patients with human epidermal growth factor receptor 2-positive SDC, with a manageable toxicity profile. Docetaxel 67-76 erb-b2 receptor tyrosine kinase 2 Homo sapiens 108-142 30316083-6 2019 The in-vivo pharmacokinetic study showed 2.33, and 2.82-fold enhancement in relative bioavailability of docetaxel for non-targeted and HER-2 receptor targeted nanoparticles, respectively than Docel . Docetaxel 104-113 erb-b2 receptor tyrosine kinase 2 Homo sapiens 135-140 29424297-9 2019 In fact, pertuzumab plus trastuzumab and docetaxel is the recommended first line regimen in HER2 positive locally recurrent or metastatic breast cancer and bevacizumab plus paclitaxel or docetaxel is a reasonable option for m-TNBC. Docetaxel 41-50 erb-b2 receptor tyrosine kinase 2 Homo sapiens 92-96 30692489-2 2018 Combination chemotherapy with pertuzumab, trastuzumab, and docetaxel is recommended as the first-line treatment for patients with HER2-positive unresectable or metastatic breast cancer. Docetaxel 59-68 erb-b2 receptor tyrosine kinase 2 Homo sapiens 130-134 29937992-4 2018 Results: we established a dose-dense docetaxel recommended dose of 60 mg/m2 and 65 mg/m2, with or without trastuzumab, respectively, according to HER2-status, following dose-dense epirubicin-cyclophosphamide (90/600 mg/m2), every 2 weeks. Docetaxel 37-46 erb-b2 receptor tyrosine kinase 2 Homo sapiens 146-150 30478962-0 2018 Exceptional responses to pertuzumab, trastuzumab, and docetaxel in human epidermal growth factor receptor-2 high expressing salivary duct carcinomas. Docetaxel 54-63 erb-b2 receptor tyrosine kinase 2 Homo sapiens 73-107 30478962-3 2018 METHODS: We report 2 cases of exceptional responses of HER2-positive salivary duct carcinomas to dual HER2 blockade and docetaxel combination and their molecular characteristics. Docetaxel 120-129 erb-b2 receptor tyrosine kinase 2 Homo sapiens 55-59 30478962-4 2018 RESULTS: A 54-year-old man with recurrent metastatic HER2 expressing salivary duct carcinoma of the parotid gland after definitive concurrent chemoradiation achieved a complete response (CR) after 6 cycles of trastuzumab, pertuzumab, and docetaxel (TPH). Docetaxel 238-247 erb-b2 receptor tyrosine kinase 2 Homo sapiens 53-57 28826287-0 2018 Docetaxel-loaded nanostructured lipid carriers functionalized with trastuzumab (Herceptin) for HER2-positive breast cancer cells. Docetaxel 0-9 erb-b2 receptor tyrosine kinase 2 Homo sapiens 95-99 28826287-14 2018 The Herceptin conjugated NLCs seem promising in oriented delivery of DTX to HER2 positive breast cancer cells. Docetaxel 69-72 erb-b2 receptor tyrosine kinase 2 Homo sapiens 76-80 29385882-0 2018 RETRACTED: Cost-utility analysis of trastuzumab combined with Docetaxel for patients with HER-2 positive metastatic breast cancer - real world claim data. Docetaxel 62-71 erb-b2 receptor tyrosine kinase 2 Homo sapiens 90-95 29205665-1 2018 While the docetaxel, carboplatin, and trastuzumab (TCH) regimen is one of the standard treatments in Her2-positive breast cancer, however, acute toxicities, especially those related to the high rate of neutropenia are consistently reported. Docetaxel 10-19 erb-b2 receptor tyrosine kinase 2 Homo sapiens 101-105 29950829-1 2018 Background: Trastuzumab plus docetaxel is a mainstay to treat HER2-positive breast cancers. Docetaxel 29-38 erb-b2 receptor tyrosine kinase 2 Homo sapiens 62-66 30396987-4 2018 pertuzumab and docetaxel in the first-line setting of human epidermal growth factor receptor 2 (HER2)-positive advanced breast cancer. Docetaxel 15-24 erb-b2 receptor tyrosine kinase 2 Homo sapiens 60-94 30396987-10 2018 CONCLUSION: Subcutaneous trastuzumab in combination with pertuzumab and docetaxel is well tolerated and effective in HER2-positive advanced breast cancer. Docetaxel 72-81 erb-b2 receptor tyrosine kinase 2 Homo sapiens 117-121 29718725-0 2018 Bispecific antibodies (anti-mPEG/anti-HER2) for active tumor targeting of docetaxel (DTX)-loaded mPEGylated nanocarriers to enhance the chemotherapeutic efficacy of HER2-overexpressing tumors. Docetaxel 74-83 erb-b2 receptor tyrosine kinase 2 Homo sapiens 38-42 29718725-0 2018 Bispecific antibodies (anti-mPEG/anti-HER2) for active tumor targeting of docetaxel (DTX)-loaded mPEGylated nanocarriers to enhance the chemotherapeutic efficacy of HER2-overexpressing tumors. Docetaxel 74-83 erb-b2 receptor tyrosine kinase 2 Homo sapiens 165-169 29718725-0 2018 Bispecific antibodies (anti-mPEG/anti-HER2) for active tumor targeting of docetaxel (DTX)-loaded mPEGylated nanocarriers to enhance the chemotherapeutic efficacy of HER2-overexpressing tumors. Docetaxel 85-88 erb-b2 receptor tyrosine kinase 2 Homo sapiens 38-42 29718725-0 2018 Bispecific antibodies (anti-mPEG/anti-HER2) for active tumor targeting of docetaxel (DTX)-loaded mPEGylated nanocarriers to enhance the chemotherapeutic efficacy of HER2-overexpressing tumors. Docetaxel 85-88 erb-b2 receptor tyrosine kinase 2 Homo sapiens 165-169 29718725-1 2018 Anti-mPEG/anti-human epidermal growth factor receptor 2 (HER2) bispecific antibodies (BsAbs) non-covalently bound to a docetaxel (DTX)-loaded mPEGylated lecithin-stabilized micellar drug delivery system (LsbMDDs) were endowed with active targetability to improve the chemotherapeutic efficacy of DTX. Docetaxel 119-128 erb-b2 receptor tyrosine kinase 2 Homo sapiens 0-55 29718725-1 2018 Anti-mPEG/anti-human epidermal growth factor receptor 2 (HER2) bispecific antibodies (BsAbs) non-covalently bound to a docetaxel (DTX)-loaded mPEGylated lecithin-stabilized micellar drug delivery system (LsbMDDs) were endowed with active targetability to improve the chemotherapeutic efficacy of DTX. Docetaxel 119-128 erb-b2 receptor tyrosine kinase 2 Homo sapiens 57-61 29718725-1 2018 Anti-mPEG/anti-human epidermal growth factor receptor 2 (HER2) bispecific antibodies (BsAbs) non-covalently bound to a docetaxel (DTX)-loaded mPEGylated lecithin-stabilized micellar drug delivery system (LsbMDDs) were endowed with active targetability to improve the chemotherapeutic efficacy of DTX. Docetaxel 130-133 erb-b2 receptor tyrosine kinase 2 Homo sapiens 0-55 29718725-1 2018 Anti-mPEG/anti-human epidermal growth factor receptor 2 (HER2) bispecific antibodies (BsAbs) non-covalently bound to a docetaxel (DTX)-loaded mPEGylated lecithin-stabilized micellar drug delivery system (LsbMDDs) were endowed with active targetability to improve the chemotherapeutic efficacy of DTX. Docetaxel 130-133 erb-b2 receptor tyrosine kinase 2 Homo sapiens 57-61 29718725-1 2018 Anti-mPEG/anti-human epidermal growth factor receptor 2 (HER2) bispecific antibodies (BsAbs) non-covalently bound to a docetaxel (DTX)-loaded mPEGylated lecithin-stabilized micellar drug delivery system (LsbMDDs) were endowed with active targetability to improve the chemotherapeutic efficacy of DTX. Docetaxel 296-299 erb-b2 receptor tyrosine kinase 2 Homo sapiens 57-61 30071039-0 2018 Germline single nucleotide polymorphisms in ERBB3 and BARD1 genes result in a worse relapse free survival response for HER2-positive breast cancer patients treated with adjuvant based docetaxel, carboplatin and trastuzumab (TCH). Docetaxel 184-193 erb-b2 receptor tyrosine kinase 2 Homo sapiens 119-123 29665663-0 2018 [Analysis of neoadjuvant docetaxel, carboplatin and trastuzumab (TCH) in HER-2-positive breast cancer]. Docetaxel 25-34 erb-b2 receptor tyrosine kinase 2 Homo sapiens 73-78 29768350-1 2018 The aim of this study is to report first preliminary results of patients enrolled in a phase II study that will investigate the activity and safety of docetaxel, oxaliplatin, and 5-fluorouracil (DOF) in combination with trastuzumab in human epidermal receptor-2 (HER-2) positive patients with advanced gastric or gastroesophageal junction (GEJ) cancer.Treatment consisted of docetaxel 70 mg/m combined with oxaliplatin 130 mg/m on day 1, and continuous infusion 5-fluorouracil mg/m days 1-5 plus trastuzumab at the standard dose on day 1, every 3 weeks for a maximum of 8 cycles.Fifteen patients were enrolled. Docetaxel 151-160 erb-b2 receptor tyrosine kinase 2 Homo sapiens 263-268 29915439-6 2018 For HER2-positive metastatic breast cancer, 82% of physicians recommended docetaxel (DTX) plus trastuzumab plus pertuzumab (DTP) as standard care for patients aged 65-70, although 54% of physicians avoided DTP for those aged 71-75 as first-line standard preference. Docetaxel 74-83 erb-b2 receptor tyrosine kinase 2 Homo sapiens 4-8 29695917-3 2018 In this study, we report the efficacy of adding trastuzumab to docetaxel in this regimen for high-risk human epidermal growth factor receptor 2 (HER2)-positive early-stage disease. Docetaxel 63-72 erb-b2 receptor tyrosine kinase 2 Homo sapiens 109-143 29695917-3 2018 In this study, we report the efficacy of adding trastuzumab to docetaxel in this regimen for high-risk human epidermal growth factor receptor 2 (HER2)-positive early-stage disease. Docetaxel 63-72 erb-b2 receptor tyrosine kinase 2 Homo sapiens 145-149 29665663-1 2018 Objective: To analyze docetaxel (T) and carboplatin (C) combined with trastuzumab (H) -TCH regimen as neoadjuvant systemic therapy in early breast cancer patients with human epidermal growth factor receptor 2 (HER-2) positive. Docetaxel 22-31 erb-b2 receptor tyrosine kinase 2 Homo sapiens 174-208 29175149-19 2018 INTERPRETATION: Traditional neoadjuvant systemic chemotherapy plus dual HER2-targeted blockade (docetaxel, carboplatin, and trastuzumab plus pertuzumab) resulted in significantly more patients achieving a pathological complete response than HER2-targeted chemotherapy plus HER2-targeted blockade (trastuzumab emtansine plus pertuzumab); however, numerically more grade 3-4 and serious adverse events occurred in the chemotherapy plus trastuzumab and pertuzumab group. Docetaxel 96-105 erb-b2 receptor tyrosine kinase 2 Homo sapiens 72-76 29416331-10 2018 Results: The obtained results demonstrated significantly enhanced in vitro cytotoxicity and cellular uptake of Apt-DTX-NPs in a HER-2-overexpressing cell line, comparing to DTX-NPs and the free drug. Docetaxel 115-118 erb-b2 receptor tyrosine kinase 2 Homo sapiens 128-133 29599915-1 2018 The standard treatment for advanced human epidermal growth factor receptor 2 (HER2)-positive breast cancer is the triple combination of pertuzumab, trastuzumab and docetaxel, but some patients cannot tolerate taxane. Docetaxel 164-173 erb-b2 receptor tyrosine kinase 2 Homo sapiens 42-76 29599915-1 2018 The standard treatment for advanced human epidermal growth factor receptor 2 (HER2)-positive breast cancer is the triple combination of pertuzumab, trastuzumab and docetaxel, but some patients cannot tolerate taxane. Docetaxel 164-173 erb-b2 receptor tyrosine kinase 2 Homo sapiens 78-82 29290024-14 2018 CONCLUSION: Trastuzumab in combination with docetaxel and S-1 showed effective antitumor activity and manageable toxicities as first-line treatment for patients with HER2-positive GC. Docetaxel 44-53 erb-b2 receptor tyrosine kinase 2 Homo sapiens 166-170 29370839-2 2018 CASE PRESENTATION: A 46 years old Caucasian woman with HER2-positive MBC and no baseline CNS involvement, started in August 2015 1st line therapy with Pertuzumab-Trastuzumab-Docetaxel, with partial response. Docetaxel 174-183 erb-b2 receptor tyrosine kinase 2 Homo sapiens 55-59 29175149-19 2018 INTERPRETATION: Traditional neoadjuvant systemic chemotherapy plus dual HER2-targeted blockade (docetaxel, carboplatin, and trastuzumab plus pertuzumab) resulted in significantly more patients achieving a pathological complete response than HER2-targeted chemotherapy plus HER2-targeted blockade (trastuzumab emtansine plus pertuzumab); however, numerically more grade 3-4 and serious adverse events occurred in the chemotherapy plus trastuzumab and pertuzumab group. Docetaxel 96-105 erb-b2 receptor tyrosine kinase 2 Homo sapiens 241-245 29175149-19 2018 INTERPRETATION: Traditional neoadjuvant systemic chemotherapy plus dual HER2-targeted blockade (docetaxel, carboplatin, and trastuzumab plus pertuzumab) resulted in significantly more patients achieving a pathological complete response than HER2-targeted chemotherapy plus HER2-targeted blockade (trastuzumab emtansine plus pertuzumab); however, numerically more grade 3-4 and serious adverse events occurred in the chemotherapy plus trastuzumab and pertuzumab group. Docetaxel 96-105 erb-b2 receptor tyrosine kinase 2 Homo sapiens 241-245 28783505-0 2017 Surface modification of docetaxel nanocrystals with HER2 antibody to enhance cell growth inhibition in breast cancer cells. Docetaxel 24-33 erb-b2 receptor tyrosine kinase 2 Homo sapiens 52-56 28982879-0 2017 Using TILs to Predict Therapeutic Effect of Chemotherapy (Pertuzumab, Trastuzumab, Docetaxel) on HER2-positive Breast Cancer. Docetaxel 83-92 erb-b2 receptor tyrosine kinase 2 Homo sapiens 97-101 29083340-1 2017 Taxanes, including paclitaxel and docetaxel, are one of the most active cytotoxic agents in breast cancer treatment including Her-2 positive subtype characterized by aggressive clinical and pathological features since the early stage. Docetaxel 34-43 erb-b2 receptor tyrosine kinase 2 Homo sapiens 129-134 29112701-1 2017 Background: Combination pertuzumab, trastuzumab, and docetaxel (D) is considered standard first-line treatment of human epidermal growth factor receptor 2 (HER2)-positive metastatic breast cancer. Docetaxel 53-62 erb-b2 receptor tyrosine kinase 2 Homo sapiens 120-154 29112701-1 2017 Background: Combination pertuzumab, trastuzumab, and docetaxel (D) is considered standard first-line treatment of human epidermal growth factor receptor 2 (HER2)-positive metastatic breast cancer. Docetaxel 53-62 erb-b2 receptor tyrosine kinase 2 Homo sapiens 156-160 28959366-7 2017 These results suggested that the mechanism underlying the synergistic efficacy of the triple-drug combination was attributable, at least in part, to the docetaxel-mediated apoptosis being promoted by enhanced inhibition of HER2-HER3-AKT signaling as well to the intratumor infiltration of mononuclear cells induced by anti-HER2 antibodies being enhanced by docetaxel. Docetaxel 153-162 erb-b2 receptor tyrosine kinase 2 Homo sapiens 223-227 28592618-15 2017 The Oncologist 2017;22:1160-1168 IMPLICATIONS FOR PRACTICE: Combined treatment with pertuzumab, trastuzumab, and docetaxel is the standard of care for first-line HER2-positive metastatic breast cancer. Docetaxel 113-122 erb-b2 receptor tyrosine kinase 2 Homo sapiens 162-166 28959366-7 2017 These results suggested that the mechanism underlying the synergistic efficacy of the triple-drug combination was attributable, at least in part, to the docetaxel-mediated apoptosis being promoted by enhanced inhibition of HER2-HER3-AKT signaling as well to the intratumor infiltration of mononuclear cells induced by anti-HER2 antibodies being enhanced by docetaxel. Docetaxel 153-162 erb-b2 receptor tyrosine kinase 2 Homo sapiens 323-327 28959366-7 2017 These results suggested that the mechanism underlying the synergistic efficacy of the triple-drug combination was attributable, at least in part, to the docetaxel-mediated apoptosis being promoted by enhanced inhibition of HER2-HER3-AKT signaling as well to the intratumor infiltration of mononuclear cells induced by anti-HER2 antibodies being enhanced by docetaxel. Docetaxel 357-366 erb-b2 receptor tyrosine kinase 2 Homo sapiens 223-227 28850174-24 2017 For HER-2 negative people, all different two-and three-drug combinations including irinotecan, docetaxel, oxaliplatin or oral 5-FU prodrugs are valid treatment options for advanced gastric cancer, and consideration of the side effects of each regimen is essential in the treatment decision. Docetaxel 95-104 erb-b2 receptor tyrosine kinase 2 Homo sapiens 4-9 28946623-7 2017 Docetaxel-encapsulating liposomes were successfully developed HER2-targeted drug delivery by coupling HER2-specific binding peptide on liposome surface. Docetaxel 0-9 erb-b2 receptor tyrosine kinase 2 Homo sapiens 62-66 28946623-7 2017 Docetaxel-encapsulating liposomes were successfully developed HER2-targeted drug delivery by coupling HER2-specific binding peptide on liposome surface. Docetaxel 0-9 erb-b2 receptor tyrosine kinase 2 Homo sapiens 102-106 28737130-12 2017 CONCLUSION: Pertuzumab + trastuzumab + docetaxel treatment significantly reduced death, increased overall survival, and progression-free survival in patients with HER2-positive metastatic breast cancer compared to placebo and trastuzumab + docetaxel treatment, but showed no increased adverse events. Docetaxel 39-48 erb-b2 receptor tyrosine kinase 2 Homo sapiens 163-167 28737130-0 2017 Effect of pertuzumab, trastuzumab, and docetaxel in HER2-positive metastatic breast cancer: A meta-analysis : . Docetaxel 39-48 erb-b2 receptor tyrosine kinase 2 Homo sapiens 52-56 27771885-0 2017 Capecitabine in Combination with Docetaxel in First Line in HER2-Negative Metastatic Breast Cancer: an Observational Study. Docetaxel 33-42 erb-b2 receptor tyrosine kinase 2 Homo sapiens 60-64 28183321-7 2017 High HER2 was significantly associated with higher pCR rates (P = 0.001) and a significant treatment interaction (P = 0.0236) with pertuzumab, trastuzumab, and docetaxel (odds ratio 2.07, P = 0.01). Docetaxel 160-169 erb-b2 receptor tyrosine kinase 2 Homo sapiens 5-9 28361910-10 2017 miR-9 targeted the Her-2 messenger RNA and increased responsiveness of BC cells to docetaxel (DOC) or cyclophosphamide treatment. Docetaxel 83-92 erb-b2 receptor tyrosine kinase 2 Homo sapiens 19-24 28361910-10 2017 miR-9 targeted the Her-2 messenger RNA and increased responsiveness of BC cells to docetaxel (DOC) or cyclophosphamide treatment. Docetaxel 94-97 erb-b2 receptor tyrosine kinase 2 Homo sapiens 19-24 28361910-11 2017 The ectopic expression of Her-2 protein counteracted the miR-9 proapoptotic activity in response to DOC. Docetaxel 100-103 erb-b2 receptor tyrosine kinase 2 Homo sapiens 26-31 28690527-2 2017 Herein, we report the case of a 67-year-old female with early-stage HER2-postitive breast cancer who developed interstitial pneumonitis during cycle 5 of treatment with trastuzumab combined with carboplatin and docetaxel. Docetaxel 211-220 erb-b2 receptor tyrosine kinase 2 Homo sapiens 68-72 28373460-1 2017 We herein report a case of locally advanced human epidermal growth factor receptor 2 (HER2)-positive breast cancer that achieved a pathological complete response (pCR) with pertuzumab, trastuzumab and docetaxel therapy. Docetaxel 201-210 erb-b2 receptor tyrosine kinase 2 Homo sapiens 50-84 28373460-1 2017 We herein report a case of locally advanced human epidermal growth factor receptor 2 (HER2)-positive breast cancer that achieved a pathological complete response (pCR) with pertuzumab, trastuzumab and docetaxel therapy. Docetaxel 201-210 erb-b2 receptor tyrosine kinase 2 Homo sapiens 86-90 28611541-0 2017 Effectiveness of Pertuzumab, Trastuzumab, and Docetaxel Combination Neoadjuvant Chemotherapy for HER2-Positive Inflammatory Breast Cancer: A Case Report. Docetaxel 46-55 erb-b2 receptor tyrosine kinase 2 Homo sapiens 97-101 28611541-4 2017 Rather than surgical intervention, we chose a systemic treatment approach with pertuzumab, trastuzumab, and docetaxel (PTD) combination therapy which was shown to be effective for HER2-positive IBC in the NeoSphere trial. Docetaxel 108-117 erb-b2 receptor tyrosine kinase 2 Homo sapiens 180-184 29199719-0 2017 Retrospective study of efficacy and safety of neoadjuvant docetaxel, carboplatin, and trastuzumab in HER2-positive locally advanced and oligometastatic breast cancer: An Indian experience. Docetaxel 58-67 erb-b2 receptor tyrosine kinase 2 Homo sapiens 101-105 27693116-1 2017 BACKGROUND: The purpose of this study was to determine the cardiac safety and clinical activity of trastuzumab and bevacizumab with docetaxel after epirubicin with cyclophosphamide (EC) in patients with HER2-positive locally advanced breast cancer (LABC) or pathologic stage 3 breast cancer (PS3BC). Docetaxel 132-141 erb-b2 receptor tyrosine kinase 2 Homo sapiens 203-207 26754092-0 2017 Docetaxel and cyclophosphamide as neoadjuvant chemotherapy in HER2-negative primary breast cancer. Docetaxel 0-9 erb-b2 receptor tyrosine kinase 2 Homo sapiens 62-66 26754092-1 2017 BACKGROUND: Docetaxel plus cyclophosphamide (TC) has recently been established as a standard adjuvant chemotherapy regimen for HER2-negative (HER2-) operable breast cancer. Docetaxel 12-21 erb-b2 receptor tyrosine kinase 2 Homo sapiens 127-131 26754092-1 2017 BACKGROUND: Docetaxel plus cyclophosphamide (TC) has recently been established as a standard adjuvant chemotherapy regimen for HER2-negative (HER2-) operable breast cancer. Docetaxel 12-21 erb-b2 receptor tyrosine kinase 2 Homo sapiens 142-146 26874836-0 2017 Docetaxel, cyclophosphamide, and trastuzumab as neoadjuvant chemotherapy for HER2-positive primary breast cancer. Docetaxel 0-9 erb-b2 receptor tyrosine kinase 2 Homo sapiens 77-81 27955684-1 2016 BACKGROUND: Pertuzumab, trastuzumab, and docetaxel is standard of care for first-line treatment of HER2-positive metastatic breast cancer (MBC). Docetaxel 41-50 erb-b2 receptor tyrosine kinase 2 Homo sapiens 99-103 26357489-11 2015 This study demonstrated that neoadjuvant FEC followed by triweekly docetaxel and/or trastuzumab did induce a high pathologic response in luminal HER2 type, but not in luminal A and B types, and did not induce a high pCR rate in the hormone-positive patients. Docetaxel 67-76 erb-b2 receptor tyrosine kinase 2 Homo sapiens 145-149 27445484-1 2016 BACKGROUND: The combined therapy of bevacizumab (BEV) with taxane (paclitaxel or docetaxel) has shown an improvement on progression-free survival (PFS) and objective remission in Her2-negative patients with locally recurrent or metastatic breast cancer (LR/MBC). Docetaxel 81-90 erb-b2 receptor tyrosine kinase 2 Homo sapiens 179-183 31149444-9 2016 Trastuzumab/docetaxel therapy can elicit a clinical and pathological response in HER2-positive SDC. Docetaxel 12-21 erb-b2 receptor tyrosine kinase 2 Homo sapiens 81-85 26392111-3 2016 We demonstrated that docetaxel-induced apoptosis and survivin upregulation (MCF7 p = 0.002, BT474 p = 0.001, SKBR3 p = 0.001) in luminal A/B and HER2-like cells, while it induced mainly necrosis and a lower rate of survivin upregulation (MDA-MB231 p = 0.035) in basal-like cells. Docetaxel 21-30 erb-b2 receptor tyrosine kinase 2 Homo sapiens 145-149 27551486-5 2015 Dominant-negative HER-2 sensitizes SK-BR-3 cells to docetaxel. Docetaxel 52-61 erb-b2 receptor tyrosine kinase 2 Homo sapiens 18-23 27551486-7 2015 The synergism of docetaxel and resveratrol was maximum in SK-BR-3, which is unique among the cell lines studied, due to its high expression status of HER-2, a receptor known to dictate the signaling environment of breast cancer cells. Docetaxel 17-26 erb-b2 receptor tyrosine kinase 2 Homo sapiens 150-155 27551486-8 2015 Docetaxel could further induce HER-2 activity in these cells, which was downregulated on resveratrol treatment. Docetaxel 0-9 erb-b2 receptor tyrosine kinase 2 Homo sapiens 31-36 27551486-9 2015 Transfection of DN-HER-2 in SK-BR-3 cells inhibits the synergism as the transfection itself sensitizes these cells to docetaxel, leaving no role for resveratrol, whereas ectopic expression of HER-2 introduces the synergism in MDA-MB-231, the triple-negative cell line, in which the synergism was minimum, attesting the crucial role of HER-2 in suppressing the sensitivity to docetaxel. Docetaxel 118-127 erb-b2 receptor tyrosine kinase 2 Homo sapiens 19-24 27551486-9 2015 Transfection of DN-HER-2 in SK-BR-3 cells inhibits the synergism as the transfection itself sensitizes these cells to docetaxel, leaving no role for resveratrol, whereas ectopic expression of HER-2 introduces the synergism in MDA-MB-231, the triple-negative cell line, in which the synergism was minimum, attesting the crucial role of HER-2 in suppressing the sensitivity to docetaxel. Docetaxel 375-384 erb-b2 receptor tyrosine kinase 2 Homo sapiens 19-24 27551486-10 2015 Single-agent docetaxel induced HER-2-mediated resistance to cell death, which was blocked by resveratrol. Docetaxel 13-22 erb-b2 receptor tyrosine kinase 2 Homo sapiens 31-36 27551486-11 2015 Resveratrol also downregulated docetaxel-induced activation of MAPK and Akt, survival signaling pathways downstream of HER-2. Docetaxel 31-40 erb-b2 receptor tyrosine kinase 2 Homo sapiens 119-124 27551486-12 2015 In short, this study, for the first time, establishes the role of HER-2-Akt signaling axis in regulating the synergistic effect of docetaxel and resveratrol in breast cancer cells overexpressing HER-2. Docetaxel 131-140 erb-b2 receptor tyrosine kinase 2 Homo sapiens 66-71 27551486-12 2015 In short, this study, for the first time, establishes the role of HER-2-Akt signaling axis in regulating the synergistic effect of docetaxel and resveratrol in breast cancer cells overexpressing HER-2. Docetaxel 131-140 erb-b2 receptor tyrosine kinase 2 Homo sapiens 195-200 26539407-3 2015 We report what we believe to be the first published case of hypersensitivity skin testing for gemcitabine-induced pneumonitis in a patient with metastatic leiomyosarcoma and another case of docetaxel-induced pneumonitis in a patient with metastatic HER2-positive breast cancer. Docetaxel 190-199 erb-b2 receptor tyrosine kinase 2 Homo sapiens 249-253 28174484-1 2016 OBJECTIVE: A previous study demonstrated that non-anthracycline-containing docetaxel plus cyclophosphamide (TC) regimen was inferior to docetaxel, anthracycline and cyclophosphamide (TAC) in neoadjuvant treatment of triple-negative breast cancer (TNBC) and human epidermal growth factor receptor-2-(HER2)-positive breast cancer in a short-term follow-up. Docetaxel 75-84 erb-b2 receptor tyrosine kinase 2 Homo sapiens 263-297 28174484-1 2016 OBJECTIVE: A previous study demonstrated that non-anthracycline-containing docetaxel plus cyclophosphamide (TC) regimen was inferior to docetaxel, anthracycline and cyclophosphamide (TAC) in neoadjuvant treatment of triple-negative breast cancer (TNBC) and human epidermal growth factor receptor-2-(HER2)-positive breast cancer in a short-term follow-up. Docetaxel 75-84 erb-b2 receptor tyrosine kinase 2 Homo sapiens 299-303 27920624-0 2016 Neoadjuvant Chemotherapy with Docetaxel, Carboplatin and Weekly Trastuzumab Is Active in HER2-Positive Early Breast Cancer: Results after a Median Follow-Up of over 4 Years. Docetaxel 30-39 erb-b2 receptor tyrosine kinase 2 Homo sapiens 89-93 27052654-2 2016 This phase Ib/IIa study assessed the feasibility of T-DM1 + docetaxel in patients with human epidermal growth factor receptor 2 (HER2)-positive metastatic breast cancer (MBC) and T-DM1 + docetaxel +- pertuzumab in patients with HER2-positive locally advanced breast cancer (LABC). Docetaxel 60-69 erb-b2 receptor tyrosine kinase 2 Homo sapiens 93-127 27052654-2 2016 This phase Ib/IIa study assessed the feasibility of T-DM1 + docetaxel in patients with human epidermal growth factor receptor 2 (HER2)-positive metastatic breast cancer (MBC) and T-DM1 + docetaxel +- pertuzumab in patients with HER2-positive locally advanced breast cancer (LABC). Docetaxel 60-69 erb-b2 receptor tyrosine kinase 2 Homo sapiens 129-133 27250913-5 2016 RESULTS: The combination of pertuzumab-trastuzumab-docetaxel has established efficacy in patients with HER2-positive metastatic breast cancer, prolonging progression-free and overall survival compared to trastuzumab-taxane combinations. Docetaxel 51-60 erb-b2 receptor tyrosine kinase 2 Homo sapiens 103-107 27052896-3 2016 In this study, we synthesized trastuzumab (TZ)-grafted dendrimers to improve delivery of docetaxel (DTX) to HER2-positive breast cancer cells. Docetaxel 89-98 erb-b2 receptor tyrosine kinase 2 Homo sapiens 108-112 27052896-3 2016 In this study, we synthesized trastuzumab (TZ)-grafted dendrimers to improve delivery of docetaxel (DTX) to HER2-positive breast cancer cells. Docetaxel 100-103 erb-b2 receptor tyrosine kinase 2 Homo sapiens 108-112 26351332-1 2016 PURPOSE: The Clinical Evaluation of Pertuzumab and Trastuzumab (CLEOPATRA) study showed a 15.7-month survival benefit with the addition of pertuzumab to docetaxel and trastuzumab (THP) as first-line treatment for patients with human epidermal growth factor receptor 2 (HER2) -overexpressing metastatic breast cancer. Docetaxel 153-162 erb-b2 receptor tyrosine kinase 2 Homo sapiens 233-267 26351332-1 2016 PURPOSE: The Clinical Evaluation of Pertuzumab and Trastuzumab (CLEOPATRA) study showed a 15.7-month survival benefit with the addition of pertuzumab to docetaxel and trastuzumab (THP) as first-line treatment for patients with human epidermal growth factor receptor 2 (HER2) -overexpressing metastatic breast cancer. Docetaxel 153-162 erb-b2 receptor tyrosine kinase 2 Homo sapiens 269-273 26116144-1 2016 The CLEOPATRA trial reported the survival benefit of pertuzumab with trastuzumab plus docetaxel in HER2-positive metastatic breast cancer patients. Docetaxel 86-95 erb-b2 receptor tyrosine kinase 2 Homo sapiens 99-103 26595802-3 2016 HER2+ BC cell lines BT474 and MDAMB361 treated with docetaxel showed up-modulation of NK activator ligands both in vitro and in vivo, accompanied by a 15-40% increase in in vitro trastuzumab-mediated ADCC; antibodies blocking the NKG2D receptor significantly reduced this enhancement. Docetaxel 52-61 erb-b2 receptor tyrosine kinase 2 Homo sapiens 0-4 26603736-7 2016 In particular, during the course of therapy, four patients in the trastuzumab-docetaxel HER2+ subgroup and two patients in the taxane HER2- subgroup had a relative decrease (>10%) in GLS. Docetaxel 78-87 erb-b2 receptor tyrosine kinase 2 Homo sapiens 88-92 27551486-0 2015 Resveratrol chemosensitizes HER-2-overexpressing breast cancer cells to docetaxel chemoresistance by inhibiting docetaxel-mediated activation of HER-2-Akt axis. Docetaxel 72-81 erb-b2 receptor tyrosine kinase 2 Homo sapiens 28-33 27551486-0 2015 Resveratrol chemosensitizes HER-2-overexpressing breast cancer cells to docetaxel chemoresistance by inhibiting docetaxel-mediated activation of HER-2-Akt axis. Docetaxel 72-81 erb-b2 receptor tyrosine kinase 2 Homo sapiens 145-150 27551486-0 2015 Resveratrol chemosensitizes HER-2-overexpressing breast cancer cells to docetaxel chemoresistance by inhibiting docetaxel-mediated activation of HER-2-Akt axis. Docetaxel 112-121 erb-b2 receptor tyrosine kinase 2 Homo sapiens 28-33 27551486-0 2015 Resveratrol chemosensitizes HER-2-overexpressing breast cancer cells to docetaxel chemoresistance by inhibiting docetaxel-mediated activation of HER-2-Akt axis. Docetaxel 112-121 erb-b2 receptor tyrosine kinase 2 Homo sapiens 145-150 27551486-2 2015 Here we demonstrate that human epidermal growth factor receptor-2 (HER-2)-overexpressing breast cancer cells resist docetaxel-induced cytotoxicity by upregulating HER-2 and its activity downstream, through Akt and mitogen-activated protein kinase (MAPK) pathways. Docetaxel 116-125 erb-b2 receptor tyrosine kinase 2 Homo sapiens 25-65 27551486-2 2015 Here we demonstrate that human epidermal growth factor receptor-2 (HER-2)-overexpressing breast cancer cells resist docetaxel-induced cytotoxicity by upregulating HER-2 and its activity downstream, through Akt and mitogen-activated protein kinase (MAPK) pathways. Docetaxel 116-125 erb-b2 receptor tyrosine kinase 2 Homo sapiens 67-72 27551486-2 2015 Here we demonstrate that human epidermal growth factor receptor-2 (HER-2)-overexpressing breast cancer cells resist docetaxel-induced cytotoxicity by upregulating HER-2 and its activity downstream, through Akt and mitogen-activated protein kinase (MAPK) pathways. Docetaxel 116-125 erb-b2 receptor tyrosine kinase 2 Homo sapiens 163-168 27551486-3 2015 We observed that introducing resveratrol as a chemosensitizer in docetaxel chemotherapy blocks upregulation and activation of HER-2 in addition to blocking downstream signaling pathways such as Akt. Docetaxel 65-74 erb-b2 receptor tyrosine kinase 2 Homo sapiens 126-131 27551486-4 2015 Resveratrol and docetaxel combination results in the synergistic induction of cell death in HER-2-overexpressing SK-BR-3 cells, whereas introduction of wild-type HER-2 in MDA-MD-231 cells increased the resistance to docetaxel. Docetaxel 16-25 erb-b2 receptor tyrosine kinase 2 Homo sapiens 92-97 26103952-12 2015 CONCLUSION: This study shows that trastuzumab-based adjuvant treatment of small HER2-positive breast cancer is mostly based on chemotherapy-mainly paclitaxel/docetaxel. Docetaxel 158-167 erb-b2 receptor tyrosine kinase 2 Homo sapiens 80-84 26622896-8 2015 The results of the present study indicate that maintenance with single agent capecitabine therapy is an effective and tolerable treatment option for HER2 negative MBC patients in which disease control with 6 cycles of docetaxel plus capecitabine chemotherapy is achieved in the first-line setting. Docetaxel 218-227 erb-b2 receptor tyrosine kinase 2 Homo sapiens 149-153 26295141-0 2015 Dual-Ligand Modified Polymer-Lipid Hybrid Nanoparticles for Docetaxel Targeting Delivery to Her2/neu Overexpressed Human Breast Cancer Cells. Docetaxel 60-69 erb-b2 receptor tyrosine kinase 2 Homo sapiens 92-100 26295141-5 2015 Upon the systemic investigation of the cellular uptake behavior of dual-ligand hybrid NPs, docetaxel (DTX), a hydrophobic anticancer drug, was successfully encapsulated into dual-ligand hybrid NPs with high drug loading for Her2/neu-overexpressing SK-BR-3 breast cancer cell treatment. Docetaxel 91-100 erb-b2 receptor tyrosine kinase 2 Homo sapiens 224-255 26295141-5 2015 Upon the systemic investigation of the cellular uptake behavior of dual-ligand hybrid NPs, docetaxel (DTX), a hydrophobic anticancer drug, was successfully encapsulated into dual-ligand hybrid NPs with high drug loading for Her2/neu-overexpressing SK-BR-3 breast cancer cell treatment. Docetaxel 102-105 erb-b2 receptor tyrosine kinase 2 Homo sapiens 224-255 26199243-1 2015 The CLEOPATRA trial showed a significant improvement in the progression-free survival (PFS) and overall survival of patients with HER2-positive first-line metastatic breast cancer (MBC) who were treated with pertuzumab (PER), trastuzumab (TRA), and docetaxel (DTX), compared to those treated with placebo, TRA, and DTX. Docetaxel 249-258 erb-b2 receptor tyrosine kinase 2 Homo sapiens 130-134 26199243-1 2015 The CLEOPATRA trial showed a significant improvement in the progression-free survival (PFS) and overall survival of patients with HER2-positive first-line metastatic breast cancer (MBC) who were treated with pertuzumab (PER), trastuzumab (TRA), and docetaxel (DTX), compared to those treated with placebo, TRA, and DTX. Docetaxel 260-263 erb-b2 receptor tyrosine kinase 2 Homo sapiens 130-134 26199243-1 2015 The CLEOPATRA trial showed a significant improvement in the progression-free survival (PFS) and overall survival of patients with HER2-positive first-line metastatic breast cancer (MBC) who were treated with pertuzumab (PER), trastuzumab (TRA), and docetaxel (DTX), compared to those treated with placebo, TRA, and DTX. Docetaxel 315-318 erb-b2 receptor tyrosine kinase 2 Homo sapiens 130-134 25879949-4 2015 METHODS: In this study, we analyzed by quantitative PCR the expression of 28 genes in HER2-overexpressing tumors treated with trastuzumab + docetaxel-based chemotherapy. Docetaxel 140-149 erb-b2 receptor tyrosine kinase 2 Homo sapiens 86-90 25963698-5 2015 Combination therapy with pertuzumab, trastuzumab, and docetaxel seems to be a useful preoperative chemotherapy regimen for HER2-positive breast cancer. Docetaxel 54-63 erb-b2 receptor tyrosine kinase 2 Homo sapiens 123-127 25879949-10 2015 The use of cancer cell lines as the reference allowed a proper fit with the specificity of different tissues, such as lung or gastric cancers, which could also be eligible to concomitant HER2 inhibition by treatment with trastuzumab or tyrosine kinase inhibitors and docetaxel. Docetaxel 267-276 erb-b2 receptor tyrosine kinase 2 Homo sapiens 187-191 25693012-0 2015 Pertuzumab, trastuzumab, and docetaxel in HER2-positive metastatic breast cancer. Docetaxel 29-38 erb-b2 receptor tyrosine kinase 2 Homo sapiens 42-46 25683304-0 2015 Balancing activity and tolerability of neoadjuvant paclitaxel- and docetaxel-based chemotherapy for HER2-positive early stage breast cancer: sensitivity analysis of randomized trials. Docetaxel 67-76 erb-b2 receptor tyrosine kinase 2 Homo sapiens 100-104 25576381-5 2015 Significantly, C6 ceramide plus docetaxel caused dramatic human epidermal growth factor receptor (HER)-1/-2 degradation and downstream Akt/Erk inhibition in HER-2 expressing MDA-231 cells. Docetaxel 32-41 erb-b2 receptor tyrosine kinase 2 Homo sapiens 157-162 25347449-1 2015 OBJECTIVE: The NeoSphere trial demonstrated that the addition of pertuzumab to trastuzumab and docetaxel for the neoadjuvant treatment of HER2-positive locally advanced, inflammatory, or early breast cancer (eBC) resulted in a significant improvement in pathological complete response (pCR). Docetaxel 95-104 erb-b2 receptor tyrosine kinase 2 Homo sapiens 138-142 25693012-1 2015 BACKGROUND: In patients with metastatic breast cancer that is positive for human epidermal growth factor receptor 2 (HER2), progression-free survival was significantly improved after first-line therapy with pertuzumab, trastuzumab, and docetaxel, as compared with placebo, trastuzumab, and docetaxel. Docetaxel 290-299 erb-b2 receptor tyrosine kinase 2 Homo sapiens 75-115 25693012-1 2015 BACKGROUND: In patients with metastatic breast cancer that is positive for human epidermal growth factor receptor 2 (HER2), progression-free survival was significantly improved after first-line therapy with pertuzumab, trastuzumab, and docetaxel, as compared with placebo, trastuzumab, and docetaxel. Docetaxel 236-245 erb-b2 receptor tyrosine kinase 2 Homo sapiens 75-115 25693012-1 2015 BACKGROUND: In patients with metastatic breast cancer that is positive for human epidermal growth factor receptor 2 (HER2), progression-free survival was significantly improved after first-line therapy with pertuzumab, trastuzumab, and docetaxel, as compared with placebo, trastuzumab, and docetaxel. Docetaxel 290-299 erb-b2 receptor tyrosine kinase 2 Homo sapiens 117-121 25693012-1 2015 BACKGROUND: In patients with metastatic breast cancer that is positive for human epidermal growth factor receptor 2 (HER2), progression-free survival was significantly improved after first-line therapy with pertuzumab, trastuzumab, and docetaxel, as compared with placebo, trastuzumab, and docetaxel. Docetaxel 236-245 erb-b2 receptor tyrosine kinase 2 Homo sapiens 117-121 25034441-3 2015 METHODS: HER2-amplified patients who received neoadjuvant trastuzumab-docetaxel were gathered. Docetaxel 70-79 erb-b2 receptor tyrosine kinase 2 Homo sapiens 9-13 25398698-1 2015 PURPOSE: To evaluate the activity and safety of the docetaxel, gemcitabine and bevacizumab combination, administered biweekly, in pretreated patients with HER-2-negative metastatic breast cancer (MBC). Docetaxel 52-61 erb-b2 receptor tyrosine kinase 2 Homo sapiens 155-160 25398698-12 2015 CONCLUSION: The combination of docetaxel, gemcitabine and bevacizumab has promising activity and manageable toxicity as salvage chemotherapy for HER-2-negative MBC patients. Docetaxel 31-40 erb-b2 receptor tyrosine kinase 2 Homo sapiens 145-150 25398698-0 2015 Docetaxel, gemcitabine and bevacizumab as salvage chemotherapy for HER-2-negative metastatic breast cancer. Docetaxel 0-9 erb-b2 receptor tyrosine kinase 2 Homo sapiens 67-72 26359224-4 2015 For human epidermal growth factor receptors 2 (HER2) negative cancer, standard treatments are combinations of fluoropyrimidine and platinum with or without epirubicin or docetaxel in first-line therapy. Docetaxel 170-179 erb-b2 receptor tyrosine kinase 2 Homo sapiens 47-51 25494663-0 2015 Pertuzumab in combination with trastuzumab and docetaxel for HER2-positive metastatic breast cancer. Docetaxel 47-56 erb-b2 receptor tyrosine kinase 2 Homo sapiens 61-65 25477120-1 2014 According to the final analysis of CLEOPATRA, first-line treatment with pertuzumab plus trastuzumab and docetaxel significantly improves overall survival for patients with HER2-positive metastatic breast cancer. Docetaxel 104-113 erb-b2 receptor tyrosine kinase 2 Homo sapiens 172-176 25138171-0 2015 Pertuzumab in combination with trastuzumab and docetaxel for the treatment of HER2-positive metastatic or locally recurrent unresectable breast cancer. Docetaxel 47-56 erb-b2 receptor tyrosine kinase 2 Homo sapiens 78-82 25138171-1 2015 The National Institute for Health and Care Excellence (NICE) invited the manufacturer of pertuzumab (Roche) to submit evidence for the clinical and cost effectiveness of pertuzumab + trastuzumab + docetaxel for the treatment of human epidermal growth factor receptor 2-positive (HER2+) metastatic or locally recurrent unresectable breast cancer in accordance with the Institute"s Single Technology Appraisal (STA) process. Docetaxel 197-206 erb-b2 receptor tyrosine kinase 2 Homo sapiens 234-268 24894652-0 2014 A Phase II study of bevacizumab in combination with trastuzumab and docetaxel in HER2 positive metastatic breast cancer. Docetaxel 68-77 erb-b2 receptor tyrosine kinase 2 Homo sapiens 81-85 25475708-9 2014 The interest of HER2-double blockade by the combination of trastuzumab-pertuzumab combined to docetaxel has been demonstrated in term of pCR in the NEOSPHERE study which also included HER2-positive IBC. Docetaxel 94-103 erb-b2 receptor tyrosine kinase 2 Homo sapiens 16-20 24894652-12 2014 CONCLUSION: The combination of bevacizumab, trastuzumab and docetaxel is well tolerated and is clinically active in patients with HER2-positive MBC, with response rate and PFS comparable to previous reports utilizing higher dose of docetaxel (100 mg/m2). Docetaxel 60-69 erb-b2 receptor tyrosine kinase 2 Homo sapiens 130-134 25548584-1 2014 PURPOSE: We evaluated the tolerability and cardiac safety of docetaxel, cyclophosphamide, and trastuzumab (TCyH) for the treatment of early-stage human epidermal growth factor receptor 2 (HER2)-positive breast cancer and compared to the standard trastuzumab-based chemotherapy regimens doxorubicin with cyclophosphamide followed by paclitaxel and trastuzumab (AC-TH) and docetaxel, carboplatin, and trastuzumab (TCaH). Docetaxel 61-70 erb-b2 receptor tyrosine kinase 2 Homo sapiens 152-186 24685829-1 2014 BACKGROUND: Results from the phase III trial CLEOPATRA in human epidermal growth factor receptor 2-positive first-line metastatic breast cancer demonstrated significant improvements in progression-free and overall survival with pertuzumab, trastuzumab, and docetaxel over placebo, trastuzumab, and docetaxel. Docetaxel 257-266 erb-b2 receptor tyrosine kinase 2 Homo sapiens 64-98 25091659-4 2014 This drug can be used in combination with trastuzumab and docetaxel for the first line treatment of metastatic or locally recurrent non resecable HER2-positive breast cancers not previously treated by chemotherapy or HER2-inhibitors in the metastatic setting. Docetaxel 58-67 erb-b2 receptor tyrosine kinase 2 Homo sapiens 146-150 24869931-1 2014 INTRODUCTION: We report detailed safety analyses by geographic region from the phase III study CLEOPATRA with pertuzumab, trastuzumab, and docetaxel in patients with human epidermal growth factor receptor 2 (HER2)-positive first-line metastatic breast cancer. Docetaxel 139-148 erb-b2 receptor tyrosine kinase 2 Homo sapiens 172-206 24869931-9 2014 The benefit-risk profile of pertuzumab, trastuzumab, and docetaxel supports this regimen as the first-line therapy for patients with HER2-positive metastatic breast cancer from all geographic regions. Docetaxel 57-66 erb-b2 receptor tyrosine kinase 2 Homo sapiens 133-137 24685829-0 2014 Incidence of central nervous system metastases in patients with HER2-positive metastatic breast cancer treated with pertuzumab, trastuzumab, and docetaxel: results from the randomized phase III study CLEOPATRA. Docetaxel 145-154 erb-b2 receptor tyrosine kinase 2 Homo sapiens 64-68 24685829-1 2014 BACKGROUND: Results from the phase III trial CLEOPATRA in human epidermal growth factor receptor 2-positive first-line metastatic breast cancer demonstrated significant improvements in progression-free and overall survival with pertuzumab, trastuzumab, and docetaxel over placebo, trastuzumab, and docetaxel. Docetaxel 298-307 erb-b2 receptor tyrosine kinase 2 Homo sapiens 64-98 24692675-3 2014 This approval for first-line therapy for metastatic breast cancer was based on the results of a large randomized multicenter phase III trial showing a significant improvement in overall survival when pertuzumab was combined with trastuzumab and docetaxel in HER2-positive metastatic breast cancer. Docetaxel 245-254 erb-b2 receptor tyrosine kinase 2 Homo sapiens 258-262 24887458-1 2014 INTRODUCTION: The purpose of this study was to retrospectively explore the relationship between human epidermal growth factor receptor 2 (HER2) messenger RNA (mRNA) expression and efficacy in patients receiving trastuzumab plus docetaxel (HT) or trastuzumab emtansine (T-DM1). Docetaxel 228-237 erb-b2 receptor tyrosine kinase 2 Homo sapiens 102-136 24887458-1 2014 INTRODUCTION: The purpose of this study was to retrospectively explore the relationship between human epidermal growth factor receptor 2 (HER2) messenger RNA (mRNA) expression and efficacy in patients receiving trastuzumab plus docetaxel (HT) or trastuzumab emtansine (T-DM1). Docetaxel 228-237 erb-b2 receptor tyrosine kinase 2 Homo sapiens 138-142 24253810-7 2013 HER2-positive patients (arm C) received docetaxel + carboplatin + trastuzumab for 52 weeks. Docetaxel 40-49 erb-b2 receptor tyrosine kinase 2 Homo sapiens 0-4 24799054-2 2014 We report the activity and safety results of biweekly combination of trastuzumab, docetaxel and gemcitabine as first-line therapy in HER2-positive advanced breast cancer. Docetaxel 82-91 erb-b2 receptor tyrosine kinase 2 Homo sapiens 133-137 24461325-2 2014 We have developed in our previous work nanoparticles of a mixture of two vitamin E TPGS based copolymers PLA-TPGS and TPGS-TOOH with the latter for Herceptin conjugation for targeted delivery of anticancer drugs such as docetaxel to the cancer cells of human epidermal growth factor receptor 2 (HER2) overexpression. Docetaxel 220-229 erb-b2 receptor tyrosine kinase 2 Homo sapiens 259-293 24461325-2 2014 We have developed in our previous work nanoparticles of a mixture of two vitamin E TPGS based copolymers PLA-TPGS and TPGS-TOOH with the latter for Herceptin conjugation for targeted delivery of anticancer drugs such as docetaxel to the cancer cells of human epidermal growth factor receptor 2 (HER2) overexpression. Docetaxel 220-229 erb-b2 receptor tyrosine kinase 2 Homo sapiens 295-299 24091128-0 2013 A multicenter phase I-II study of docetaxel plus epirubicin plus bevacizumab as first-line treatment in women with HER2-negative metastatic breast cancer. Docetaxel 34-43 erb-b2 receptor tyrosine kinase 2 Homo sapiens 115-119 25374186-0 2014 Modified docetaxel and cisplatin in combination with capecitabine (DCX) as a first-line treatment in HER2-negative advanced gastric cancer. Docetaxel 9-18 erb-b2 receptor tyrosine kinase 2 Homo sapiens 101-105 24352574-0 2014 A phase II study of docetaxel and vinorelbine plus filgrastim for HER-2 negative, stage IV breast cancer: SWOG S0102. Docetaxel 20-29 erb-b2 receptor tyrosine kinase 2 Homo sapiens 66-71 24352574-16 2014 The combination of docetaxel and vinorelbine is an active first-line chemotherapy in HER-2 nonoverexpressing, metastatic breast cancer. Docetaxel 19-28 erb-b2 receptor tyrosine kinase 2 Homo sapiens 85-90 24134122-8 2013 Finally, different healthy and tumoral breast-cell lines were cultured in vitro with Nile-Red-loaded and docetaxel-loaded HER2 immuno-nanocapsules. Docetaxel 105-114 erb-b2 receptor tyrosine kinase 2 Homo sapiens 122-126 24007746-15 2013 INTERPRETATION: A short, four-cycle regimen of docetaxel and cyclophosphamide combined with trastuzumab could be an option for adjuvant treatment of women with lower risk HER2-amplified early breast cancer, irrespective of TOP2A status. Docetaxel 47-56 erb-b2 receptor tyrosine kinase 2 Homo sapiens 171-175 23868905-1 2013 BACKGROUND: The phase III CLEOPATRA study demonstrated that combining pertuzumab with trastuzumab plus docetaxel significantly improves progression-free and overall survival in previously untreated HER2-positive metastatic breast cancer. Docetaxel 103-112 erb-b2 receptor tyrosine kinase 2 Homo sapiens 198-202 23403395-6 2013 The targeting effects of the HTCP NPs were demonstrated by a much lower IC50 value of 0.0201+0.00780+0.1629mug/mL of docetaxel+cisplatin+herceptin for SK-BR-3 cells, which are of high HER2 overexpression, than that of 0.225+0.0875+1.827mug/mL for NIH3T3 cells, which are of low HER2 overexpression, after 24h incubation. Docetaxel 117-126 erb-b2 receptor tyrosine kinase 2 Homo sapiens 184-188 23878115-9 2013 CONCLUSIONS: Lapatinib/docetaxel/trastuzumab is a feasible and well-tolerated treatment of untreated HER2-positive stage IV MBC. Docetaxel 23-32 erb-b2 receptor tyrosine kinase 2 Homo sapiens 101-105 23569311-1 2013 PURPOSE The AVEREL trial [A Study of Avastin (Bevacizumab) in Combination With Herceptin (Trastuzumab)/Docetaxel in Patients With HER2-Positive Metastatic Breast Cancer] evaluated first-line bevacizumab-containing therapy for human epidermal growth factor receptor 2 (HER2) -positive locally recurrent/metastatic breast cancer (LR/MBC). Docetaxel 103-112 erb-b2 receptor tyrosine kinase 2 Homo sapiens 130-134 23332349-0 2013 Final results from phase II trial of neoadjuvant docetaxel and capecitabine given sequentially or concurrently for HER2-negative breast cancers. Docetaxel 49-58 erb-b2 receptor tyrosine kinase 2 Homo sapiens 115-119 22833344-9 2013 CONCLUSIONS: PST including concurrent use of trastuzumab combined with docetaxel is effective and well-tolerated in HER-2-positive advanced breast cancer patients, including those patients requiring mastectomy for local control. Docetaxel 71-80 erb-b2 receptor tyrosine kinase 2 Homo sapiens 116-121 24025504-0 2013 [Clinical paired study of comparing docetaxel plus capecitabine versus docetaxel plus epirubicin as first-line treatment in women with HER-2 negative advanced breast cancer]. Docetaxel 36-45 erb-b2 receptor tyrosine kinase 2 Homo sapiens 135-140 23602601-19 2013 INTERPRETATION: Our analysis shows a significant improvement in overall survival with pertuzumab, trastuzumab, and docetaxel in patients with HER2-positive metastatic breast cancer, compared with placebo, trastuzumab, and docetaxel. Docetaxel 115-124 erb-b2 receptor tyrosine kinase 2 Homo sapiens 142-146 23530718-5 2013 The combination of pertuzumab, trastuzumab and docetaxel has been found to have an OS benefit in patients with HER2 positive metastatic breast cancer (MBC) when used in the first-line setting. Docetaxel 47-56 erb-b2 receptor tyrosine kinase 2 Homo sapiens 111-115 23602601-19 2013 INTERPRETATION: Our analysis shows a significant improvement in overall survival with pertuzumab, trastuzumab, and docetaxel in patients with HER2-positive metastatic breast cancer, compared with placebo, trastuzumab, and docetaxel. Docetaxel 222-231 erb-b2 receptor tyrosine kinase 2 Homo sapiens 142-146 23422754-0 2013 Biomarker results from the AVADO phase 3 trial of first-line bevacizumab plus docetaxel for HER2-negative metastatic breast cancer. Docetaxel 78-87 erb-b2 receptor tyrosine kinase 2 Homo sapiens 92-96 23479679-2 2013 EXPERIMENTAL DESIGN: We conducted an RNA interference (RNAi) screen within the breast cancer genome for genes whose loss-of-function enhanced docetaxel chemosensitivity in an estrogen receptor-negative, progesterone receptor-negative, and Her2-negative (ER-, PR-, and Her2-, respectively) breast cancer cell line, MDA-MB-231. Docetaxel 142-151 erb-b2 receptor tyrosine kinase 2 Homo sapiens 239-243 23479679-2 2013 EXPERIMENTAL DESIGN: We conducted an RNA interference (RNAi) screen within the breast cancer genome for genes whose loss-of-function enhanced docetaxel chemosensitivity in an estrogen receptor-negative, progesterone receptor-negative, and Her2-negative (ER-, PR-, and Her2-, respectively) breast cancer cell line, MDA-MB-231. Docetaxel 142-151 erb-b2 receptor tyrosine kinase 2 Homo sapiens 268-272 23479679-6 2013 Decreased expression of KIF14, but not TLN1, also enhanced docetaxel sensitivity in a Her2-amplified breast cancer cell line, SUM190PT. Docetaxel 59-68 erb-b2 receptor tyrosine kinase 2 Homo sapiens 86-90 23354013-7 2013 CCK-8 assay indicated that the inhibition of ErbB-2 expression increased the sensitivity of BT474 cells to docetaxel treatment. Docetaxel 119-128 erb-b2 receptor tyrosine kinase 2 Homo sapiens 45-51 23450278-1 2013 BACKGROUND: We report on the activity of the combination of epirubicin and docetaxel given in neoadjuvant setting for 4 and 8 cycles respectively in 2 successive series of patients with large operable or locally advanced, hormone receptor positive, HER-2 negative breast cancer. Docetaxel 75-84 erb-b2 receptor tyrosine kinase 2 Homo sapiens 249-254 22999386-9 2013 CONCLUSIONS: Our recommended dose for phase II is lapatinib 1000mg/day and docetaxel 100mg/m(2) with G-CSF in HER2 positive non-metastatic breast cancer. Docetaxel 75-84 erb-b2 receptor tyrosine kinase 2 Homo sapiens 110-114 24083754-0 2013 Feasibility study of docetaxel and cyclophosphamide six- cycle therapy as adjuvant chemotherapy for Japanese human epidermal growth factor receptor 2-negative breast cancer patients. Docetaxel 21-30 erb-b2 receptor tyrosine kinase 2 Homo sapiens 115-149 23814044-0 2013 Health-related quality of life with adjuvant docetaxel- and trastuzumab-based regimens in patients with node-positive and high-risk node-negative, HER2-positive early breast cancer: results from the BCIRG 006 Study. Docetaxel 45-54 erb-b2 receptor tyrosine kinase 2 Homo sapiens 147-151 23564368-0 2013 Thrombotic microangiopathy during docetaxel, trastuzumab, and carboplatin chemotherapy for early-stage HER2+ breast cancer: a case report. Docetaxel 34-43 erb-b2 receptor tyrosine kinase 2 Homo sapiens 103-107 22270929-11 2012 The improvement in DFS with docetaxel-containing regimens was observed across all subgroups (age, under or over 50; number of involved nodes; hormone receptor or HER2 status (including triple negative status), or administration schedule (sequential or concomitant). Docetaxel 28-37 erb-b2 receptor tyrosine kinase 2 Homo sapiens 162-166 23235175-0 2012 [A case of HER2-positive and AFP-producing gastric cancer successfully treated by trastuzumab/docetaxel/S-1 combination therapy]. Docetaxel 94-103 erb-b2 receptor tyrosine kinase 2 Homo sapiens 11-15 23235175-8 2012 Trastuzumab, docetaxel, and S-1 combination chemotherapy promise to be one of the effective treatments for HER2-positive and AFP-producing gastric cancer that have no indication for radical cure excision. Docetaxel 13-22 erb-b2 receptor tyrosine kinase 2 Homo sapiens 107-111 23170307-4 2012 Pertuzumab is approved as first-line therapy in combination with trastuzumab and docetaxel for HER2-positive metastatic breast cancer, with future opportunities to investigate its efficacy in other stages of breast cancer, as well as in the treatment of other malignancies. Docetaxel 81-90 erb-b2 receptor tyrosine kinase 2 Homo sapiens 95-99 22782294-2 2012 It was recently approved by the US FDA for use in combination with trastuzumab and docetaxel for patients with HER2-positive metastatic breast cancer who have not received prior anti-HER2 therapy or chemotherapy for metastatic disease. Docetaxel 83-92 erb-b2 receptor tyrosine kinase 2 Homo sapiens 111-115 22534547-0 2012 Trastuzumab combined with docetaxel-based regimens in previously treated metastatic gastric cancer patients with HER2 over-expression. Docetaxel 26-35 erb-b2 receptor tyrosine kinase 2 Homo sapiens 113-117 22534547-1 2012 BACKGROUND/AIMS: This study evaluates the efficacy and safety of trastuzumab combined with docetaxel-based chemotherapy in previously treated metastatic gastric carcinoma of Chinese patients with HER2 over-expression. Docetaxel 91-100 erb-b2 receptor tyrosine kinase 2 Homo sapiens 196-200 22534547-14 2012 CONCLUSIONS: Combinations of trastuzumab plus docetaxel-based regimens were well tolerated and effective in previously treated metastatic gastric cancer of Chinese patients with HER2 over-expression or gene amplification. Docetaxel 46-55 erb-b2 receptor tyrosine kinase 2 Homo sapiens 178-182 21373875-10 2012 Capecitabine plus docetaxel in HER2-negative, and with trastuzumab in HER2-positive patients, provided a good response rate with four cycles of non-anthracycline-containing therapy. Docetaxel 18-27 erb-b2 receptor tyrosine kinase 2 Homo sapiens 31-35 22387177-0 2012 NRF2 inhibition represses ErbB2 signaling in ovarian carcinoma cells: implications for tumor growth retardation and docetaxel sensitivity. Docetaxel 116-125 erb-b2 receptor tyrosine kinase 2 Homo sapiens 26-31 22387177-7 2012 Furthermore, NRF2 inhibition-mediated ErbB2 repression increases the sensitivity of these cells to docetaxel cytotoxicity and apoptosis. Docetaxel 99-108 erb-b2 receptor tyrosine kinase 2 Homo sapiens 38-43 22387177-8 2012 The linkage between NRF2 and ErbB2 was confirmed in the ErbB2-positive breast cancer cell line BT-474: NRF2 knockdown suppressed ErbB2 expression and enhanced docetaxel sensitivity. Docetaxel 159-168 erb-b2 receptor tyrosine kinase 2 Homo sapiens 29-34 22349922-1 2012 PURPOSE: Preclinical data indicate that the combination of docetaxel, cisplatin and trastuzumab (TCH) may have the potential for clinically significant activity against breast cancers that overexpress the her2/neu gene (HER2). Docetaxel 59-68 erb-b2 receptor tyrosine kinase 2 Homo sapiens 205-213 22349922-1 2012 PURPOSE: Preclinical data indicate that the combination of docetaxel, cisplatin and trastuzumab (TCH) may have the potential for clinically significant activity against breast cancers that overexpress the her2/neu gene (HER2). Docetaxel 59-68 erb-b2 receptor tyrosine kinase 2 Homo sapiens 220-224 23007148-3 2012 We report the treatment outcome in 3 patients with HER2-positive metastatic gastric cancer who were treated with trastuzumab plus the triplet FLOT regimen (5-fluorouracil/leucovorin, oxaliplatin, and docetaxel). Docetaxel 200-209 erb-b2 receptor tyrosine kinase 2 Homo sapiens 51-55 22331954-1 2012 PURPOSE: To investigate whether sunitinib plus docetaxel improves clinical outcomes for patients with human epidermal growth factor receptor 2 (HER2)/neu-negative advanced breast cancer (ABC) versus docetaxel alone. Docetaxel 47-56 erb-b2 receptor tyrosine kinase 2 Homo sapiens 108-142 22112931-0 2012 Multicenter, phase II, nonrandomized study of docetaxel plus trastuzumab every 21 days as the primary therapy in metastatic breast cancer overexpressing HER2. Docetaxel 46-55 erb-b2 receptor tyrosine kinase 2 Homo sapiens 153-157 22112931-12 2012 First-line trastuzumab combined with docetaxel is an effective and well tolerated regimen for HER2+ MBC. Docetaxel 37-46 erb-b2 receptor tyrosine kinase 2 Homo sapiens 94-98 22149875-10 2012 CONCLUSIONS: The combination of pertuzumab plus trastuzumab plus docetaxel, as compared with placebo plus trastuzumab plus docetaxel, when used as first-line treatment for HER2-positive metastatic breast cancer, significantly prolonged progression-free survival, with no increase in cardiac toxic effects. Docetaxel 65-74 erb-b2 receptor tyrosine kinase 2 Homo sapiens 172-176 23002126-18 2012 Only two previous randomized studies have compared the efficacy of single agent docetaxel and vinorelbine following prior anthracycline exposure, one in an unselected population [16], and the other, HERNATA, in HER2 positive disease with trastuzumab used in both arms [17]. Docetaxel 80-89 erb-b2 receptor tyrosine kinase 2 Homo sapiens 211-215 23007148-9 2012 CONCLUSION: This report provides the first evidence that the addition of trastuzumab to a docetaxel-based, triple-drug chemotherapy combination is feasible and highly active in patients with HER2-positive metastatic gastric cancer. Docetaxel 90-99 erb-b2 receptor tyrosine kinase 2 Homo sapiens 191-195 22014264-0 2011 Antisense oligodeoxynucleotide targeting HER2 mRNA sensitized docetaxel in breast cancer treatment. Docetaxel 62-71 erb-b2 receptor tyrosine kinase 2 Homo sapiens 41-45 21826527-1 2011 SWOG trial S0102 showed significant activity of the combination of docetaxel and vinorelbine in HER2-negative metastatic breast cancer (MBC). Docetaxel 67-76 erb-b2 receptor tyrosine kinase 2 Homo sapiens 96-100 21826527-2 2011 For HER2-positive patients, additional benefit may occur with the addition of trastuzumab due to its synergy with docetaxel and vinorelbine. Docetaxel 114-123 erb-b2 receptor tyrosine kinase 2 Homo sapiens 4-8 21826527-15 2011 The combination of trastuzumab, docetaxel, and vinorelbine is effective as first-line chemotherapy in HER2-positive MBC with minimal toxicity. Docetaxel 32-41 erb-b2 receptor tyrosine kinase 2 Homo sapiens 102-106 21918347-0 2011 [A case of effective combination therapy with docetaxel, cyclophosphamide and trastuzumab as primary systemic therapy for locally advanced HER2-positive breast cancer]. Docetaxel 46-55 erb-b2 receptor tyrosine kinase 2 Homo sapiens 139-143 21665463-13 2011 CONCLUSIONS: The combination of Myocet , docetaxel and trastuzumab is safe and shows promising activity as first-line treatment of HER-2-positive MBC. Docetaxel 41-50 erb-b2 receptor tyrosine kinase 2 Homo sapiens 131-136 21481270-0 2011 Evaluation of HER2 and p53 expression in predicting response to docetaxel-based first-line chemotherapy in advanced breast cancer. Docetaxel 64-73 erb-b2 receptor tyrosine kinase 2 Homo sapiens 14-18 21750556-0 2011 T-bet expression in intratumoral lymphoid structures after neoadjuvant trastuzumab plus docetaxel for HER2-overexpressing breast carcinoma predicts survival. Docetaxel 88-97 erb-b2 receptor tyrosine kinase 2 Homo sapiens 102-106 21335337-4 2011 Since the human epidermal growth factor receptor 2 status of her gastric cancer specimen was strongly positive, docetaxel plus trastuzumab was administered for three cycles. Docetaxel 112-121 erb-b2 receptor tyrosine kinase 2 Homo sapiens 16-50 21481270-2 2011 We explore the value of HER2 and p53 status to foretell docetaxel sensitivity in advanced breast cancer. Docetaxel 56-65 erb-b2 receptor tyrosine kinase 2 Homo sapiens 24-28 21481270-15 2011 CONCLUSION: Our data seem to indicate that FISH-determined HER2 status but not p53 is associated with docetaxel sensitivity in metastatic breast cancer. Docetaxel 102-111 erb-b2 receptor tyrosine kinase 2 Homo sapiens 59-63 20693300-7 2011 CONCLUSION: This is the first report of LTFU showing that anthracycline-free trastuzumab-based PST combined either with docetaxel and/or carboplatin can achieve, without cardiac toxicity, very competitive results in terms of pathological complete response, RFS and OS, in HER2+BC. Docetaxel 120-129 erb-b2 receptor tyrosine kinase 2 Homo sapiens 272-276 21115860-0 2011 Multicenter phase III randomized trial comparing docetaxel and trastuzumab with docetaxel, carboplatin, and trastuzumab as first-line chemotherapy for patients with HER2-gene-amplified metastatic breast cancer (BCIRG 007 study): two highly active therapeutic regimens. Docetaxel 49-58 erb-b2 receptor tyrosine kinase 2 Homo sapiens 165-169 21149659-1 2011 PURPOSE: To evaluate docetaxel or vinorelbine, both with trastuzumab, as first-line therapy of human epidermal growth factor receptor 2-positive advanced breast cancer. Docetaxel 21-30 erb-b2 receptor tyrosine kinase 2 Homo sapiens 101-135 21115860-0 2011 Multicenter phase III randomized trial comparing docetaxel and trastuzumab with docetaxel, carboplatin, and trastuzumab as first-line chemotherapy for patients with HER2-gene-amplified metastatic breast cancer (BCIRG 007 study): two highly active therapeutic regimens. Docetaxel 80-89 erb-b2 receptor tyrosine kinase 2 Homo sapiens 165-169 20603435-0 2011 Phase II clinical trial of liposomal-encapsulated doxorubicin citrate and docetaxel, associated with trastuzumab, as neoadjuvant treatment in stages II and IIIA HER2-overexpressing breast cancer patients. Docetaxel 74-83 erb-b2 receptor tyrosine kinase 2 Homo sapiens 161-165 21115860-1 2011 PURPOSE: Docetaxel-trastuzumab (TH) is effective therapy for HER2-amplified metastatic breast cancer (MBC). Docetaxel 9-18 erb-b2 receptor tyrosine kinase 2 Homo sapiens 61-65 21931485-8 2011 CONCLUSION: The cytotoxicity of the immunonanocarriers against HER2-positive cell lines was significantly higher than that of nontargeted PLGA nanoparticles and free docetaxel. Docetaxel 166-175 erb-b2 receptor tyrosine kinase 2 Homo sapiens 63-67 20472435-0 2010 Phase II study of preoperative systemic treatment with the combination of docetaxel and trastuzumab in patients with locally advanced HER-2-overexpressing breast cancer. Docetaxel 74-83 erb-b2 receptor tyrosine kinase 2 Homo sapiens 134-139 21931485-0 2011 Docetaxel immunonanocarriers as targeted delivery systems for HER 2-positive tumor cells: preparation, characterization, and cytotoxicity studies. Docetaxel 0-9 erb-b2 receptor tyrosine kinase 2 Homo sapiens 62-67 20864169-5 2010 Anti-HER2 antibody (heceptin), which targets the breast cancer cells of HER2 receptor overexpression, was conjugated on the drug-loaded PLGA-PEG/PLGA nanoparticles for sustained, controlled and targeted delivery of docetaxel. Docetaxel 215-224 erb-b2 receptor tyrosine kinase 2 Homo sapiens 5-9 20472435-1 2010 We conducted a phase II study using docetaxel and trastuzumab as preoperative systemic treatment for locally advanced HER-2-overexpressing breast cancer (stage IIIB or IIIC) to evaluate the efficacy and safety, and to perform a subset analysis based on tumor biomarkers. Docetaxel 36-45 erb-b2 receptor tyrosine kinase 2 Homo sapiens 118-123 20472435-8 2010 The combination of docetaxel and trastuzumab produced highly favorable clinical and pathological responses for locally advanced HER-2-overexpressing breast cancer. Docetaxel 19-28 erb-b2 receptor tyrosine kinase 2 Homo sapiens 128-133 19380452-2 2009 We analyzed the predictive value of Ki67, HER2, and progesterone receptor (PR) expression for the efficacy of docetaxel in patients with ER-positive, node-positive breast cancer. Docetaxel 110-119 erb-b2 receptor tyrosine kinase 2 Homo sapiens 42-46 20683054-0 2010 Trastuzumab plus capecitabine and docetaxel as first-line therapy for HER2-positive metastatic breast cancer: phase II results. Docetaxel 34-43 erb-b2 receptor tyrosine kinase 2 Homo sapiens 70-74 20683054-4 2010 PATIENTS AND METHODS: HER-2-positive patients who had received adjuvant anthracyclines received docetaxel at 75 mg/m(2) on day 1 and capecitabine 950 mg/m(2)/day, days 1-14, every 3 weeks until disease progression or unacceptable toxicity. Docetaxel 96-105 erb-b2 receptor tyrosine kinase 2 Homo sapiens 22-27 20683054-13 2010 CONCLUSION: These data confirm that the combination of trastuzumab plus capecitabine and docetaxel is highly active in patients with HER-2-overexpressing anthracycline-pretreated breast cancer, offering a significant survival benefit and is well tolerated. Docetaxel 89-98 erb-b2 receptor tyrosine kinase 2 Homo sapiens 133-138 19741502-0 2009 Docetaxel first-line therapy in HER2-negative advanced breast cancer: a cohort study in patients with prospectively determined HER2 status. Docetaxel 0-9 erb-b2 receptor tyrosine kinase 2 Homo sapiens 32-36 19741502-0 2009 Docetaxel first-line therapy in HER2-negative advanced breast cancer: a cohort study in patients with prospectively determined HER2 status. Docetaxel 0-9 erb-b2 receptor tyrosine kinase 2 Homo sapiens 127-131 19741502-2 2009 This retrospective study was aimed at assessing the outcome and prognostic factors for survival of patients with HER2-negative tumors receiving first-line docetaxel-based chemotherapy for advanced breast cancer (ABC). Docetaxel 155-164 erb-b2 receptor tyrosine kinase 2 Homo sapiens 113-117 19741502-8 2009 HER2-negative, HR-positive ABC patients have a relatively good prognostic after docetaxel-containing first-line therapy. Docetaxel 80-89 erb-b2 receptor tyrosine kinase 2 Homo sapiens 0-4 20705564-0 2010 A phase II trial of docetaxel with bevacizumab as first-line therapy for HER2-negative metastatic breast cancer (TORI B01). Docetaxel 20-29 erb-b2 receptor tyrosine kinase 2 Homo sapiens 73-77 20238327-19 2010 Two and three-drug regimens including 5-FU, cisplatin, with or without an anthracycline, as well as irinotecan or docetaxel-containing regimens are reasonable treatment options for HER-2 negative patients. Docetaxel 114-123 erb-b2 receptor tyrosine kinase 2 Homo sapiens 181-186 20122160-1 2010 BACKGROUND: Combinations of trastuzumab with either docetaxel or vinorelbine are considered valuable treatment options for HER2-positive metastatic breast cancer patients. Docetaxel 52-61 erb-b2 receptor tyrosine kinase 2 Homo sapiens 123-127 20122160-3 2010 METHODS: From a multi-institutional database we retrieved 179 patients treated with either docetaxel or vinorelbine plus trastuzumab as first-line therapy for HER2-positive advanced breast cancer. Docetaxel 91-100 erb-b2 receptor tyrosine kinase 2 Homo sapiens 159-163 20122160-6 2010 CONCLUSION: Docetaxel or vinorelbine, when combined with trastuzumab, provide excellent rates of tumor control in patients with previously untreated HER2-positive advanced breast cancer. Docetaxel 12-21 erb-b2 receptor tyrosine kinase 2 Homo sapiens 149-153 19250795-14 2009 CONCLUSIONS: The 22% pCR rate in a HER2-negative population suggests that addition of bevacizumab increases the activity of neoadjuvant capecitabine-docetaxel. Docetaxel 149-158 erb-b2 receptor tyrosine kinase 2 Homo sapiens 35-39 19509167-9 2009 PI3K inhibition also rendered HER2-amplified BT-474M1 cells and tumor xenografts more sensitive to docetaxel. Docetaxel 99-108 erb-b2 receptor tyrosine kinase 2 Homo sapiens 30-34 19299236-1 2009 BACKGROUND: The combinations of trastuzumab/docetaxel and trastuzumab/vinorelbine are highly active in the treatment of patients with HER2-positive metastatic breast cancer (MBC). Docetaxel 44-53 erb-b2 receptor tyrosine kinase 2 Homo sapiens 134-138 19424599-0 2009 Transcriptome changes induced by docetaxel in human mammary cell lines expressing different levels of ERBB2. Docetaxel 33-42 erb-b2 receptor tyrosine kinase 2 Homo sapiens 102-107 19424599-5 2009 In the present study, we sought to identify genes involved in ERBB2-mediated chemoresistance to docetaxel. Docetaxel 96-105 erb-b2 receptor tyrosine kinase 2 Homo sapiens 62-67 19424599-10 2009 Our study provides a comprehensive view of the expression changes induced in two human mammary cells expressing different levels of ERBB2 in response to docetaxel that could contribute to the elucidation of the mechanisms involved in ERBB2-mediated chemoresistance in breast cancer. Docetaxel 153-162 erb-b2 receptor tyrosine kinase 2 Homo sapiens 132-137 19424599-10 2009 Our study provides a comprehensive view of the expression changes induced in two human mammary cells expressing different levels of ERBB2 in response to docetaxel that could contribute to the elucidation of the mechanisms involved in ERBB2-mediated chemoresistance in breast cancer. Docetaxel 153-162 erb-b2 receptor tyrosine kinase 2 Homo sapiens 234-239 19299236-16 2009 CONCLUSION: The combination of trastuzumab, docetaxel, and vinorelbine is highly active as first-line treatment for patients with HER2-positive MBC. Docetaxel 44-53 erb-b2 receptor tyrosine kinase 2 Homo sapiens 130-134 19505246-6 2009 The trastuzumab-functionalized, docetaxel-loaded NPs have great potential for targeted chemotherapy to treat HER2-overexpressing cancer. Docetaxel 32-41 erb-b2 receptor tyrosine kinase 2 Homo sapiens 109-113 19074216-0 2009 Phase I clinical trial of liposomal-encapsulated doxorubicin citrate and docetaxel, associated with trastuzumab, as neo-adjuvant treatment in stages II and IIIA, HER2-overexpressing breast cancer patients. Docetaxel 73-82 erb-b2 receptor tyrosine kinase 2 Homo sapiens 162-166 19299236-3 2009 PATIENTS AND METHODS: Sixty patients with previously untreated, measurable HER2-positive MBC (immunohistochemistry 3+ and/or fluorescence in situ hybridization positive) were treated with docetaxel 30 mg/m2 intravenously (I.V.) Docetaxel 188-197 erb-b2 receptor tyrosine kinase 2 Homo sapiens 75-79 18405406-5 2009 We followed the biological model of breast cancer, whereby two-thirds of human epidermal growth factor receptor 2 positive patients respond to a combination of docetaxel and human epidermal growth factor receptor 2 blocker (trastuzumab). Docetaxel 160-169 erb-b2 receptor tyrosine kinase 2 Homo sapiens 79-113 19068453-0 2008 A multicentre phase II study to evaluate sequential docetaxel followed by capecitabine treatment in anthracycline-pretreated HER-2-negative patients with metastatic breast cancer. Docetaxel 52-61 erb-b2 receptor tyrosine kinase 2 Homo sapiens 125-130 19409087-14 2009 CONCLUSIONS: The findings indicate that the 267/Dt drug combination confers increased (synergistic) therapeutic efficacy towards human breast cancer cells that express low levels of Her2. Docetaxel 48-50 erb-b2 receptor tyrosine kinase 2 Homo sapiens 182-186 18281755-8 2008 Recent studies in this area have demonstrated various mechanisms involved in the anti-tumor activity of docetaxel: (1) efflux (p-glycoprotein), (2) metabolism (CYP3A4), (3) beta-tubulin (isotype class I and III), (4) cell cycle (HER2, BRCA1), (5) apoptosis (p53, Bcl-2, thioredoxin), and (6) cell proliferation (MIB-1, nuclear grade). Docetaxel 104-113 erb-b2 receptor tyrosine kinase 2 Homo sapiens 229-233 18448549-0 2008 Trastuzumab plus paclitaxel or docetaxel in HER-2-negative/HER-2 ECD-positive anthracycline- and taxane-refractory advanced breast cancer. Docetaxel 31-40 erb-b2 receptor tyrosine kinase 2 Homo sapiens 44-49 18448549-0 2008 Trastuzumab plus paclitaxel or docetaxel in HER-2-negative/HER-2 ECD-positive anthracycline- and taxane-refractory advanced breast cancer. Docetaxel 31-40 erb-b2 receptor tyrosine kinase 2 Homo sapiens 59-64 19169606-0 2008 [Optimal role of docetaxel in adjuvant chemotherapy for early stage HER2-negative breast cancer]. Docetaxel 17-26 erb-b2 receptor tyrosine kinase 2 Homo sapiens 68-72 19169606-5 2008 At present, docetaxel-based combinations represent an appropriate choice in the adjuvant treatment of HER2-negative breast cancer, and several studies are ongoing aiming at a better evaluation of the efficacy of this agent in order to optimize its role. Docetaxel 12-21 erb-b2 receptor tyrosine kinase 2 Homo sapiens 102-106 19169607-0 2008 Docetaxel in the adjuvant therapy of HER-2 positive breast cancer patients. Docetaxel 0-9 erb-b2 receptor tyrosine kinase 2 Homo sapiens 37-42 18766004-10 2008 These results demonstrated that the relative efficacy of nab-paclitaxel was significantly higher compared with polysorbate-based docetaxel in HER2-negative tumors (three of three) and in HER2-positive tumors with high levels of SPARC. Docetaxel 129-138 erb-b2 receptor tyrosine kinase 2 Homo sapiens 142-146 18799033-0 2008 [Efficacy and toxicity of trastuzumab combined with docetaxel for Her-2/neu overexpressing metastatic breast cancer]. Docetaxel 52-61 erb-b2 receptor tyrosine kinase 2 Homo sapiens 66-71 18799033-5 2008 This study was to evaluate the efficacy and toxicity of trastuzumab combined with docetaxel in the treatment for metastatic breast cancer patients with overexpressed Her-2/neu. Docetaxel 82-91 erb-b2 receptor tyrosine kinase 2 Homo sapiens 166-175 18799033-17 2008 CONCLUSION: Trastuzumab combined with docetaxel is an effective and well-tolerated therapy for Her-2/neu overexpressing metastatic breast cancer. Docetaxel 38-47 erb-b2 receptor tyrosine kinase 2 Homo sapiens 95-104 17998285-0 2008 Serum HER2 extracellular domain predicts an aggressive clinical outcome and biological PSA response in hormone-independent prostate cancer patients treated with docetaxel. Docetaxel 161-170 erb-b2 receptor tyrosine kinase 2 Homo sapiens 6-10 17998285-12 2008 CONCLUSIONS: High HER2 ECD levels in serum are associated with a worst clinical outcome of HIPC patients treated with docetaxel. Docetaxel 118-127 erb-b2 receptor tyrosine kinase 2 Homo sapiens 18-22 18270380-0 2008 High pathologic complete response in HER 2-positive locally advanced breast cancer after primary systemic chemotherapy with weekly docetaxel and epirubicin. Docetaxel 131-140 erb-b2 receptor tyrosine kinase 2 Homo sapiens 37-42 18270380-9 2008 CONCLUSION: PST with weekly docetaxel and epirubicin were well-tolerated and very high pathological complete response rate was achieved in HER-2/neu-overexpression tumors. Docetaxel 28-37 erb-b2 receptor tyrosine kinase 2 Homo sapiens 145-148 18034988-6 2007 In contrast, docetaxel was significantly less effective in HER2/neu-positive patients. Docetaxel 13-22 erb-b2 receptor tyrosine kinase 2 Homo sapiens 59-63 21479380-0 2008 Relationship between the signal ratios of HER-2/CEP17 and c-MYC/CEP17 and the pathological response of neoadjuvant therapy using docetaxel and trastuzumab in breast cancer. Docetaxel 129-138 erb-b2 receptor tyrosine kinase 2 Homo sapiens 42-47 18034988-6 2007 In contrast, docetaxel was significantly less effective in HER2/neu-positive patients. Docetaxel 13-22 erb-b2 receptor tyrosine kinase 2 Homo sapiens 64-67 17324279-0 2007 HER-2, p53, p21 and hormonal receptors proteins expression as predictive factors of response and prognosis in locally advanced breast cancer treated with neoadjuvant docetaxel plus epirubicin combination. Docetaxel 166-175 erb-b2 receptor tyrosine kinase 2 Homo sapiens 0-5 17370037-8 2007 The present report has demonstrated encouraging activity of the docetaxel-ifosfamide combination in anthracycline-pretreated, HER2-negative advanced breast cancer. Docetaxel 64-73 erb-b2 receptor tyrosine kinase 2 Homo sapiens 126-130 19804028-0 2007 Docetaxel plus trastuzumab as treatment for HER-2 positive metastatic breast cancer: review of the existing evidence. Docetaxel 0-9 erb-b2 receptor tyrosine kinase 2 Homo sapiens 44-49 19804028-1 2007 The aim of this review is to examine the evidence available supporting the use of the docetaxel plus trastuzumab combination for patients with HER-2-positive metastatic breast cancer. Docetaxel 86-95 erb-b2 receptor tyrosine kinase 2 Homo sapiens 143-148 17449250-0 2007 The erbB2+ cluster of the intrinsic gene set predicts tumor response of breast cancer patients receiving neoadjuvant chemotherapy with docetaxel, doxorubicin and cyclophosphamide within the GEPARTRIO trial. Docetaxel 135-144 erb-b2 receptor tyrosine kinase 2 Homo sapiens 4-9 17592672-7 2007 Recent data on cardiac safety of taxane/trastuzumab-based combination regimens demonstrate that the docetaxel/carboplatin/trastuzumab triple combination can offer clinical efficacy with a low risk of cardiac dysfunction in patients with HER2-overexpressing early-stage breast cancer as well as in patients with metastatic breast cancer. Docetaxel 100-109 erb-b2 receptor tyrosine kinase 2 Homo sapiens 237-241 17370037-0 2007 Docetaxel-ifosfamide combination in patients with HER2-non-overexpressing advanced breast cancer failing prior anthracyclines. Docetaxel 0-9 erb-b2 receptor tyrosine kinase 2 Homo sapiens 50-54 17515572-16 2007 CONCLUSION: PST with trastuzumab plus docetaxel and carboplatin achieved promising efficacy, with a good pCR rate and favorable tolerability in stage II or III HER-2-positive breast cancer. Docetaxel 38-47 erb-b2 receptor tyrosine kinase 2 Homo sapiens 160-165 17296975-1 2007 PURPOSE: To evaluate the combination of docetaxel, vinorelbine, and trastuzumab as neoadjuvant therapy for human epidermal growth factor receptor 2 (HER2)--overexpressing breast cancer. Docetaxel 40-49 erb-b2 receptor tyrosine kinase 2 Homo sapiens 113-147 17296975-1 2007 PURPOSE: To evaluate the combination of docetaxel, vinorelbine, and trastuzumab as neoadjuvant therapy for human epidermal growth factor receptor 2 (HER2)--overexpressing breast cancer. Docetaxel 40-49 erb-b2 receptor tyrosine kinase 2 Homo sapiens 149-153 17296975-9 2007 CONCLUSION: With clinical response and pCR rates of 94% and 39%, respectively, docetaxel, vinorelbine, and trastuzumab is a highly active neoadjuvant therapy for HER2-overexpressing locally advanced breast cancer. Docetaxel 79-88 erb-b2 receptor tyrosine kinase 2 Homo sapiens 162-166 17324279-13 2007 Clinical response is inversely correlated with a risk of death in patients submitted to neoadjuvant chemotherapy and HER2 overexpression is the major prognostic factor in stage II and III breast cancer patients treated with a neoadjuvant docetaxel and epirubicin combination. Docetaxel 238-247 erb-b2 receptor tyrosine kinase 2 Homo sapiens 117-121 17211467-7 2007 We show that in addition to its known effects on tubulin and mitotic spindles, docetaxel induces complex signalisation pathway mechanisms in surviving cells, including HER2, which can be pharmacologically targeted. Docetaxel 79-88 erb-b2 receptor tyrosine kinase 2 Homo sapiens 168-172 17010609-0 2007 Gene expression profiling of breast cancer patients treated with docetaxel, doxorubicin, and cyclophosphamide within the GEPARTRIO trial: HER-2, but not topoisomerase II alpha and microtubule-associated protein tau, is highly predictive of tumor response. Docetaxel 65-74 erb-b2 receptor tyrosine kinase 2 Homo sapiens 138-143 17211467-1 2007 Antitumour activity of docetaxel (Taxotere) in hormone-dependent (HD) and hormone-independent (HID) prostate cancer PAC120 xenograft model was previously reported, and its level was associated with HER2 protein expression. Docetaxel 23-32 erb-b2 receptor tyrosine kinase 2 Homo sapiens 198-202 17211467-1 2007 Antitumour activity of docetaxel (Taxotere) in hormone-dependent (HD) and hormone-independent (HID) prostate cancer PAC120 xenograft model was previously reported, and its level was associated with HER2 protein expression. Docetaxel 34-42 erb-b2 receptor tyrosine kinase 2 Homo sapiens 198-202 17211467-8 2007 This study suggests that the docetaxel/trastuzumab combination may prove an effective therapeutic approach for HER2-expressing hormone-refractory prostate cancer. Docetaxel 29-38 erb-b2 receptor tyrosine kinase 2 Homo sapiens 111-115 17211467-2 2007 In the present study, we evaluate the antitumour effects of docetaxel combined with trastuzumab (Herceptin), an anti-HER2 antibody. Docetaxel 60-69 erb-b2 receptor tyrosine kinase 2 Homo sapiens 117-121 17033229-8 2006 The combination of docetaxel and trastuzumab was a well-tolerated and very active regimen for the treatment of patients with HER 2-overexpressing operable breast cancer. Docetaxel 19-28 erb-b2 receptor tyrosine kinase 2 Homo sapiens 125-130 16805818-8 2006 Various biological parameters have been studied clinically for their ability to predict response to docetaxel, such as parameters related to: (1) efflux (p-glycoprotein) and metabolism (CYP3A4); (2) beta-tubulin (somatic mutation of beta-tubulin and changes in beta-tubulin isotypes levels); (3) cell cycle (HER2, BRCA1 and Aurora-A); and (4) apoptosis (p53, BCL2 and thioredoxin). Docetaxel 100-109 erb-b2 receptor tyrosine kinase 2 Homo sapiens 308-312 16549824-0 2006 Docetaxel, cisplatin, and trastuzumab as primary systemic therapy for human epidermal growth factor receptor 2-positive locally advanced breast cancer. Docetaxel 0-9 erb-b2 receptor tyrosine kinase 2 Homo sapiens 76-110 16912526-0 2006 [Biweekly docetaxel and weekly trastuzumab treatment in HER 2-overexpressing metastatic breast cancer patients]. Docetaxel 10-19 erb-b2 receptor tyrosine kinase 2 Homo sapiens 56-61 16912526-1 2006 Docetaxel and trastuzumab can be considered to be active drugs for HER 2-overexpressing metastatic breast cancer (MBC). Docetaxel 0-9 erb-b2 receptor tyrosine kinase 2 Homo sapiens 67-72 16549824-1 2006 PURPOSE: To evaluate the efficacy and safety of docetaxel, cisplatin, and trastuzumab as primary systemic therapy for human epidermal growth factor receptor 2 (HER2) -positive, locally advanced breast cancer (LABC). Docetaxel 48-57 erb-b2 receptor tyrosine kinase 2 Homo sapiens 124-158 16549824-1 2006 PURPOSE: To evaluate the efficacy and safety of docetaxel, cisplatin, and trastuzumab as primary systemic therapy for human epidermal growth factor receptor 2 (HER2) -positive, locally advanced breast cancer (LABC). Docetaxel 48-57 erb-b2 receptor tyrosine kinase 2 Homo sapiens 160-164 15834928-0 2005 HER-2/neu expression as a predictor of response to neoadjuvant docetaxel in patients with operable breast carcinoma. Docetaxel 63-72 erb-b2 receptor tyrosine kinase 2 Homo sapiens 0-9 16332965-0 2006 Pre-operative systemic (neo-adjuvant) therapy with trastuzumab and docetaxel for HER2-overexpressing stage II or III breast cancer: results of a multicenter phase II trial. Docetaxel 67-76 erb-b2 receptor tyrosine kinase 2 Homo sapiens 81-85 16332965-15 2006 CONCLUSIONS: PST with trastuzumab plus docetaxel achieved promising efficacy, with a high pCR rate and good tolerability, in women with stage II or III HER2-positive breast cancer. Docetaxel 39-48 erb-b2 receptor tyrosine kinase 2 Homo sapiens 152-156 16495393-11 2006 A short course of trastuzumab administered concomitantly with docetaxel or vinorelbine is effective in women with breast cancer who have an amplified HER2/neu gene. Docetaxel 62-71 erb-b2 receptor tyrosine kinase 2 Homo sapiens 150-158 16199990-0 2005 Hypofractionated accelerated radiotherapy with cytoprotection combined with trastuzumab, liposomal doxorubicine, and docetaxel in c-erbB-2-positive breast cancer. Docetaxel 117-126 erb-b2 receptor tyrosine kinase 2 Homo sapiens 130-138 16755112-0 2006 Combination docetaxel and trastuzumab treatment for patients with HER-2-overexpressing metastatic breast cancer: a multicenter, phase-II study. Docetaxel 12-21 erb-b2 receptor tyrosine kinase 2 Homo sapiens 66-71 16755112-1 2006 BACKGROUND: Pre-clinical and clinical studies indicate that a combination of docetaxel and trastuzumab may effectively treat patients with human epidermal growth factor receptor-2 (HER-2) overexpressing metastatic breast cancer. Docetaxel 77-86 erb-b2 receptor tyrosine kinase 2 Homo sapiens 145-179 16755112-1 2006 BACKGROUND: Pre-clinical and clinical studies indicate that a combination of docetaxel and trastuzumab may effectively treat patients with human epidermal growth factor receptor-2 (HER-2) overexpressing metastatic breast cancer. Docetaxel 77-86 erb-b2 receptor tyrosine kinase 2 Homo sapiens 181-186 16315942-1 2005 PURPOSE: We report two patients with refractory recurrent breast cancer (HER2/neu: +) postoperatively, who had failed response to the available conventional chemotherapy of CAF (cyclophosphamide, adriamycin, 5-fluorouracil) and docetaxel, etc. Docetaxel 228-237 erb-b2 receptor tyrosine kinase 2 Homo sapiens 73-77 15911866-1 2005 PURPOSE: This randomized, multicenter trial compared first-line trastuzumab plus docetaxel versus docetaxel alone in patients with human epidermal growth factor receptor 2 (HER2) -positive metastatic breast cancer (MBC). Docetaxel 81-90 erb-b2 receptor tyrosine kinase 2 Homo sapiens 137-171 15834928-6 2005 RESULTS: In a multivariate analysis that controlled for tumor size and lymph node status, improved cPOS rates were observed with the addition of docetaxel in women with HER-2/neu-negative tumors (81% vs. 51%; P < 0.05), yielding an adjusted odds ratio of 3.5 (95% confidence interval, 1.2-13.0) in favor of docetaxel. Docetaxel 145-154 erb-b2 receptor tyrosine kinase 2 Homo sapiens 169-174 15834928-6 2005 RESULTS: In a multivariate analysis that controlled for tumor size and lymph node status, improved cPOS rates were observed with the addition of docetaxel in women with HER-2/neu-negative tumors (81% vs. 51%; P < 0.05), yielding an adjusted odds ratio of 3.5 (95% confidence interval, 1.2-13.0) in favor of docetaxel. Docetaxel 145-154 erb-b2 receptor tyrosine kinase 2 Homo sapiens 175-178 15834928-9 2005 CONCLUSIONS: HER-2/neu status may predict improved clinical response rates from the addition of docetaxel to anthracycline-based neoadjuvant chemotherapy. Docetaxel 96-105 erb-b2 receptor tyrosine kinase 2 Homo sapiens 13-18 15834928-9 2005 CONCLUSIONS: HER-2/neu status may predict improved clinical response rates from the addition of docetaxel to anthracycline-based neoadjuvant chemotherapy. Docetaxel 96-105 erb-b2 receptor tyrosine kinase 2 Homo sapiens 19-22 15834928-10 2005 Docetaxel may "rescue" the response in women who have HER-2/neu-negative tumors to match that observed in women who have HER-2/neu-positive tumors treated with AC alone. Docetaxel 0-9 erb-b2 receptor tyrosine kinase 2 Homo sapiens 54-59 15834928-10 2005 Docetaxel may "rescue" the response in women who have HER-2/neu-negative tumors to match that observed in women who have HER-2/neu-positive tumors treated with AC alone. Docetaxel 0-9 erb-b2 receptor tyrosine kinase 2 Homo sapiens 60-63 15834928-10 2005 Docetaxel may "rescue" the response in women who have HER-2/neu-negative tumors to match that observed in women who have HER-2/neu-positive tumors treated with AC alone. Docetaxel 0-9 erb-b2 receptor tyrosine kinase 2 Homo sapiens 121-126 15834928-10 2005 Docetaxel may "rescue" the response in women who have HER-2/neu-negative tumors to match that observed in women who have HER-2/neu-positive tumors treated with AC alone. Docetaxel 0-9 erb-b2 receptor tyrosine kinase 2 Homo sapiens 127-130 15791816-0 2005 [Study of three-weekly docetaxel and weekly trastuzumab treatment in HER 2-overexpressing metastatic breast cancer patients]. Docetaxel 23-32 erb-b2 receptor tyrosine kinase 2 Homo sapiens 69-74 15791816-1 2005 Docetaxel and trastuzumab can be considered to be active drugs for HER 2-overexpressing metastatic breast cancer (MBC). Docetaxel 0-9 erb-b2 receptor tyrosine kinase 2 Homo sapiens 67-72 15791816-11 2005 The combination of docetaxel and trastuzumab was a well-tolerated and very active regimen for the treatment of pts with HER 2-overexpressing MBC. Docetaxel 19-28 erb-b2 receptor tyrosine kinase 2 Homo sapiens 120-125 15748465-0 2005 Weekly docetaxel/carboplatin as primary systemic therapy for HER2-negative locally advanced breast cancer. Docetaxel 7-16 erb-b2 receptor tyrosine kinase 2 Homo sapiens 61-65 15366720-6 2004 The advantage of the combination with docetaxel was most pronounced in patients with 1-3 positive nodes and those with HER 2 overexpression in their tumour. Docetaxel 38-47 erb-b2 receptor tyrosine kinase 2 Homo sapiens 119-124 15567936-0 2004 HER-2/neu as a predictive marker in a population of advanced breast cancer patients randomly treated either with single-agent doxorubicin or single-agent docetaxel. Docetaxel 154-163 erb-b2 receptor tyrosine kinase 2 Homo sapiens 0-9 15567936-11 2004 CONCLUSIONS: These results suggest that in HER-2 positive breast cancer patients docetaxel might be more active than doxorubicin, while in HER-2 negative patients doxorubicin might be at least as effective as docetaxel. Docetaxel 81-90 erb-b2 receptor tyrosine kinase 2 Homo sapiens 43-48 15585076-13 2004 The results of this study suggest that the docetaxel/cisplatin combination can be an effective and well-tolerated induction treatment of LABC, even in very large mostly HER2-nonoverexpressing tumors. Docetaxel 43-52 erb-b2 receptor tyrosine kinase 2 Homo sapiens 169-173 15325672-1 2004 We report on the case of a patient with a diagnosis of a HER2-overexpressing metastatic breast cancer which was refractory to a combination of a Raf kinase inhibitor and docetaxel, but highly sensitive to trastuzumab, a HER2-targeted monoclonal antibody. Docetaxel 170-179 erb-b2 receptor tyrosine kinase 2 Homo sapiens 57-61 15150304-0 2004 Results of two open-label, multicenter phase II studies of docetaxel, platinum salts, and trastuzumab in HER2-positive advanced breast cancer. Docetaxel 59-68 erb-b2 receptor tyrosine kinase 2 Homo sapiens 105-109 15138562-0 2004 Omega-6 polyunsaturated fatty acid gamma-linolenic acid (18:3n-6) enhances docetaxel (Taxotere) cytotoxicity in human breast carcinoma cells: Relationship to lipid peroxidation and HER-2/neu expression. Docetaxel 86-94 erb-b2 receptor tyrosine kinase 2 Homo sapiens 181-190 15311558-0 2004 Safety and efficacy of the combination of trastuzumab with docetaxel for HER2-positive women with advanced breast cancer. Docetaxel 59-68 erb-b2 receptor tyrosine kinase 2 Homo sapiens 73-77 15150304-1 2004 BACKGROUND: Preclinical data indicate that docetaxel, platinum salts, and the combination of both drugs are highly synergistic with the anti-HER2 antibody trastuzumab. Docetaxel 43-52 erb-b2 receptor tyrosine kinase 2 Homo sapiens 141-145 15150304-16 2004 CONCLUSION: Combinations of docetaxel, a platinum salt, and trastuzumab are feasible and active in patients with advanced breast cancers that overexpress HER2. Docetaxel 28-37 erb-b2 receptor tyrosine kinase 2 Homo sapiens 154-158 15074734-1 2004 AIMS: To study the toxicity profile and effectiveness of combination of trastuzumab and docetaxel in women with metastatic breast cancer showing HER-2 overexpression (IHC 3+). Docetaxel 88-97 erb-b2 receptor tyrosine kinase 2 Homo sapiens 145-150 15139054-0 2004 Trastuzumab plus docetaxel in HER-2/neu-positive prostate carcinoma: final results from the California Cancer Consortium Screening and Phase II Trial. Docetaxel 17-26 erb-b2 receptor tyrosine kinase 2 Homo sapiens 30-35 15139054-3 2004 The authors screened for HER-2 overexpression in patients developing hormone-refractory prostate carcinoma (HRPC) and conducted a Phase II trial of trastuzumab plus docetaxel in HER-2-positive patients. Docetaxel 165-174 erb-b2 receptor tyrosine kinase 2 Homo sapiens 178-183 15074734-12 2004 CONCLUSION: The combination of trastuzumab and docetaxel in women with metastatic breast cancer showing HER-2 overexpression (IHC 3+) is a safe and effective regimen. Docetaxel 47-56 erb-b2 receptor tyrosine kinase 2 Homo sapiens 104-109 14967075-0 2004 Trastuzumab plus docetaxel in HER2/neu-positive non-small-cell lung cancer: a California Cancer Consortium screening and phase II trial. Docetaxel 17-26 erb-b2 receptor tyrosine kinase 2 Homo sapiens 30-34 15023243-1 2004 This study was designed to determine the efficacy and toxicity of weekly docetaxel in metastatic breast cancer when given alone (for HER2/neu negative disease) or with trastuzumab (for HER2/neu overexpressing disease). Docetaxel 73-82 erb-b2 receptor tyrosine kinase 2 Homo sapiens 133-137 15023243-11 2004 Weekly docetaxel/trastuzumab is an effective regimen for patients with HER2/neu overexpressing metastatic breast cancer. Docetaxel 7-16 erb-b2 receptor tyrosine kinase 2 Homo sapiens 71-75 15020608-0 2004 Docetaxel combined with trastuzumab is an active regimen in HER-2 3+ overexpressing and fluorescent in situ hybridization-positive metastatic breast cancer: a multi-institutional phase II trial. Docetaxel 0-9 erb-b2 receptor tyrosine kinase 2 Homo sapiens 60-65 15020608-1 2004 PURPOSE: To determine the efficacy and safety of weekly docetaxel and trastuzumab as first- or second-line therapy in women with HER-2-overexpressing metastatic breast cancer and to correlate the efficacy of trastuzumab with HER-2 status as determined by immunohistochemistry assay and fluorescent in situ hybridization (FISH). Docetaxel 56-65 erb-b2 receptor tyrosine kinase 2 Homo sapiens 129-134 15020608-10 2004 CONCLUSION: Trastuzumab plus docetaxel is an active and well-tolerated regimen in women with HER-2 3+ overexpressing or FISH-positive metastatic breast cancer. Docetaxel 29-38 erb-b2 receptor tyrosine kinase 2 Homo sapiens 93-98 14999148-0 2004 Inhibition of tumor-associated fatty acid synthase hyperactivity induces synergistic chemosensitization of HER -2/ neu -overexpressing human breast cancer cells to docetaxel (taxotere). Docetaxel 164-173 erb-b2 receptor tyrosine kinase 2 Homo sapiens 107-113 14999148-0 2004 Inhibition of tumor-associated fatty acid synthase hyperactivity induces synergistic chemosensitization of HER -2/ neu -overexpressing human breast cancer cells to docetaxel (taxotere). Docetaxel 164-173 erb-b2 receptor tyrosine kinase 2 Homo sapiens 115-118 14999148-0 2004 Inhibition of tumor-associated fatty acid synthase hyperactivity induces synergistic chemosensitization of HER -2/ neu -overexpressing human breast cancer cells to docetaxel (taxotere). Docetaxel 175-183 erb-b2 receptor tyrosine kinase 2 Homo sapiens 107-113 14999148-0 2004 Inhibition of tumor-associated fatty acid synthase hyperactivity induces synergistic chemosensitization of HER -2/ neu -overexpressing human breast cancer cells to docetaxel (taxotere). Docetaxel 175-183 erb-b2 receptor tyrosine kinase 2 Homo sapiens 115-118 14999148-4 2004 Co-administration of docetaxel (Taxotere) and the mycotoxin cerulenin, a potent and non-competitive inhibitor of FAS activity, demonstrated strong synergism in HER -2/ neu -overexpressing and docetaxel-resistant SK-Br3 cells, modest synergism in moderately HER -2/ neu -expressing MCF-7 cells, and it showed additive effects in low HER -2/ neu -expressing and docetaxel-sensitive MDA-MB-231 cells. Docetaxel 21-30 erb-b2 receptor tyrosine kinase 2 Homo sapiens 160-166 14999148-4 2004 Co-administration of docetaxel (Taxotere) and the mycotoxin cerulenin, a potent and non-competitive inhibitor of FAS activity, demonstrated strong synergism in HER -2/ neu -overexpressing and docetaxel-resistant SK-Br3 cells, modest synergism in moderately HER -2/ neu -expressing MCF-7 cells, and it showed additive effects in low HER -2/ neu -expressing and docetaxel-sensitive MDA-MB-231 cells. Docetaxel 21-30 erb-b2 receptor tyrosine kinase 2 Homo sapiens 168-171 14999148-4 2004 Co-administration of docetaxel (Taxotere) and the mycotoxin cerulenin, a potent and non-competitive inhibitor of FAS activity, demonstrated strong synergism in HER -2/ neu -overexpressing and docetaxel-resistant SK-Br3 cells, modest synergism in moderately HER -2/ neu -expressing MCF-7 cells, and it showed additive effects in low HER -2/ neu -expressing and docetaxel-sensitive MDA-MB-231 cells. Docetaxel 21-30 erb-b2 receptor tyrosine kinase 2 Homo sapiens 257-263 14999148-4 2004 Co-administration of docetaxel (Taxotere) and the mycotoxin cerulenin, a potent and non-competitive inhibitor of FAS activity, demonstrated strong synergism in HER -2/ neu -overexpressing and docetaxel-resistant SK-Br3 cells, modest synergism in moderately HER -2/ neu -expressing MCF-7 cells, and it showed additive effects in low HER -2/ neu -expressing and docetaxel-sensitive MDA-MB-231 cells. Docetaxel 21-30 erb-b2 receptor tyrosine kinase 2 Homo sapiens 265-268 14999148-4 2004 Co-administration of docetaxel (Taxotere) and the mycotoxin cerulenin, a potent and non-competitive inhibitor of FAS activity, demonstrated strong synergism in HER -2/ neu -overexpressing and docetaxel-resistant SK-Br3 cells, modest synergism in moderately HER -2/ neu -expressing MCF-7 cells, and it showed additive effects in low HER -2/ neu -expressing and docetaxel-sensitive MDA-MB-231 cells. Docetaxel 21-30 erb-b2 receptor tyrosine kinase 2 Homo sapiens 160-171 14999148-4 2004 Co-administration of docetaxel (Taxotere) and the mycotoxin cerulenin, a potent and non-competitive inhibitor of FAS activity, demonstrated strong synergism in HER -2/ neu -overexpressing and docetaxel-resistant SK-Br3 cells, modest synergism in moderately HER -2/ neu -expressing MCF-7 cells, and it showed additive effects in low HER -2/ neu -expressing and docetaxel-sensitive MDA-MB-231 cells. Docetaxel 32-40 erb-b2 receptor tyrosine kinase 2 Homo sapiens 160-166 14999148-4 2004 Co-administration of docetaxel (Taxotere) and the mycotoxin cerulenin, a potent and non-competitive inhibitor of FAS activity, demonstrated strong synergism in HER -2/ neu -overexpressing and docetaxel-resistant SK-Br3 cells, modest synergism in moderately HER -2/ neu -expressing MCF-7 cells, and it showed additive effects in low HER -2/ neu -expressing and docetaxel-sensitive MDA-MB-231 cells. Docetaxel 32-40 erb-b2 receptor tyrosine kinase 2 Homo sapiens 168-171 14999148-4 2004 Co-administration of docetaxel (Taxotere) and the mycotoxin cerulenin, a potent and non-competitive inhibitor of FAS activity, demonstrated strong synergism in HER -2/ neu -overexpressing and docetaxel-resistant SK-Br3 cells, modest synergism in moderately HER -2/ neu -expressing MCF-7 cells, and it showed additive effects in low HER -2/ neu -expressing and docetaxel-sensitive MDA-MB-231 cells. Docetaxel 32-40 erb-b2 receptor tyrosine kinase 2 Homo sapiens 257-263 14999148-4 2004 Co-administration of docetaxel (Taxotere) and the mycotoxin cerulenin, a potent and non-competitive inhibitor of FAS activity, demonstrated strong synergism in HER -2/ neu -overexpressing and docetaxel-resistant SK-Br3 cells, modest synergism in moderately HER -2/ neu -expressing MCF-7 cells, and it showed additive effects in low HER -2/ neu -expressing and docetaxel-sensitive MDA-MB-231 cells. Docetaxel 32-40 erb-b2 receptor tyrosine kinase 2 Homo sapiens 265-268 14999148-4 2004 Co-administration of docetaxel (Taxotere) and the mycotoxin cerulenin, a potent and non-competitive inhibitor of FAS activity, demonstrated strong synergism in HER -2/ neu -overexpressing and docetaxel-resistant SK-Br3 cells, modest synergism in moderately HER -2/ neu -expressing MCF-7 cells, and it showed additive effects in low HER -2/ neu -expressing and docetaxel-sensitive MDA-MB-231 cells. Docetaxel 32-40 erb-b2 receptor tyrosine kinase 2 Homo sapiens 160-171 15017597-0 2004 A case of metastatic breast cancer with outgrowth of HER2-negative cells after eradication of HER2-positive cells by humanized anti-HER2 monoclonal antibody (trastuzumab) combined with docetaxel. Docetaxel 185-194 erb-b2 receptor tyrosine kinase 2 Homo sapiens 53-57 15031597-13 2004 CONCLUSIONS: Three-weekly doses of docetaxel and a weekly dose of trastuzumab is an active and safe combination in patients with HER2-overexpressing advanced breast cancer. Docetaxel 35-44 erb-b2 receptor tyrosine kinase 2 Homo sapiens 129-133 14715110-13 2003 Combined neoadjuvant trastuzumab and docetaxel induced high clinical response rates for HER2-overexpressing breast cancer, in particular for inflammatory breast cancer. Docetaxel 37-46 erb-b2 receptor tyrosine kinase 2 Homo sapiens 88-92 14703068-0 2003 Influence of neoadjuvant therapy with epirubicin and docetaxel on the expression of HER2/neu in patients with breast cancer. Docetaxel 53-62 erb-b2 receptor tyrosine kinase 2 Homo sapiens 84-88 14703068-0 2003 Influence of neoadjuvant therapy with epirubicin and docetaxel on the expression of HER2/neu in patients with breast cancer. Docetaxel 53-62 erb-b2 receptor tyrosine kinase 2 Homo sapiens 89-92 14703068-2 2003 Since neoadjuvant chemotherapy with epirubicin and docetaxel is increasingly used in advanced breast cancer, our purpose was to assess the influence of this neoadjuvant chemotherapy on the expression of the growth factor receptor HER2/neu. Docetaxel 51-60 erb-b2 receptor tyrosine kinase 2 Homo sapiens 230-238 12576925-8 2003 In HER-2/neu transfected MCF/18 cells, docetaxel treatment resulted in a dose-dependent inhibition similar to that seen in MCF/neo cells. Docetaxel 39-48 erb-b2 receptor tyrosine kinase 2 Homo sapiens 3-12 12902864-5 2003 This study examines the effects of combining a cyclooxygenase-2 inhibitor with zoledronic acid and/or docetaxel in a HER-2/neu transfected and control human breast cancer cell line. Docetaxel 102-111 erb-b2 receptor tyrosine kinase 2 Homo sapiens 117-126 12820439-1 2003 In this study we describe and discuss the dichotomous effects of docetaxel trastuzumab (Herceptin)/docetaxel therapy on the angiogenic molecular profile in two patients with her-2 + chemo-resistant recurrent breast carcinoma. Docetaxel 65-74 erb-b2 receptor tyrosine kinase 2 Homo sapiens 174-179 12820439-1 2003 In this study we describe and discuss the dichotomous effects of docetaxel trastuzumab (Herceptin)/docetaxel therapy on the angiogenic molecular profile in two patients with her-2 + chemo-resistant recurrent breast carcinoma. Docetaxel 99-108 erb-b2 receptor tyrosine kinase 2 Homo sapiens 174-179 12820439-10 2003 Such an effect should be of clinical importance since Herceptin/Docetaxel-based regimens are currently evaluated for the adjuvant therapy of her-2 + breast cancer patients. Docetaxel 64-73 erb-b2 receptor tyrosine kinase 2 Homo sapiens 141-146 12576925-0 2003 Decreased response to paclitaxel versus docetaxel in HER-2/neu transfected human breast cancer cells. Docetaxel 40-49 erb-b2 receptor tyrosine kinase 2 Homo sapiens 53-62 12576925-9 2003 Paclitaxel, however, gave significantly less growth inhibition than docetaxel in the HER-2/neu overexpressing MCF/18 cells (p = 0.0003). Docetaxel 68-77 erb-b2 receptor tyrosine kinase 2 Homo sapiens 85-94 12576925-12 2003 Therefore, docetaxel may be the preferred taxane therapy in HER-2/neu overexpressing breast tumors. Docetaxel 11-20 erb-b2 receptor tyrosine kinase 2 Homo sapiens 60-69 12576933-0 2003 Safety and activity of docetaxel and trastuzumab in HER2 overexpressing metastatic breast cancer: a pilot phase II study. Docetaxel 23-32 erb-b2 receptor tyrosine kinase 2 Homo sapiens 52-56 12576933-1 2003 We conducted a pilot phase II trial of trastuzumab administered concurrently with docetaxel in women with HER2-overexpressing advanced breast cancer. Docetaxel 82-91 erb-b2 receptor tyrosine kinase 2 Homo sapiens 106-110 12419746-11 2002 CONCLUSIONS: The present study shows that at least additive interactions are observed when trastuzumab is combined with either paclitaxel or docetaxel in weak to moderate or more than moderate HER2-expressing cells. Docetaxel 141-150 erb-b2 receptor tyrosine kinase 2 Homo sapiens 193-197 12435858-11 2002 More significantly, the combination of intravenously administered ligand-liposome-AS HER-2 ODN and docetaxel resulted in a marked inhibition of xenograft growth in an aggressive breast cancer model that does not overexpress HER-2, even after treatment ended. Docetaxel 99-108 erb-b2 receptor tyrosine kinase 2 Homo sapiens 224-229 12173324-5 2002 The authors report the results of HER-2 screening from a Phase II trial of chemotherapy with trastuzumab and docetaxel in patients with HER-2-overexpressing prostate carcinoma. Docetaxel 109-118 erb-b2 receptor tyrosine kinase 2 Homo sapiens 34-39 12108894-9 2002 In addition, the results of the triple-drug combination of docetaxel, a platinum salt (cisplatin or carboplatin), and trastuzumab have resulted in impressive response rates and time to progression in a population of metastatic breast cancer patients with HER2/neu-positive tumors. Docetaxel 59-68 erb-b2 receptor tyrosine kinase 2 Homo sapiens 255-259 12108894-9 2002 In addition, the results of the triple-drug combination of docetaxel, a platinum salt (cisplatin or carboplatin), and trastuzumab have resulted in impressive response rates and time to progression in a population of metastatic breast cancer patients with HER2/neu-positive tumors. Docetaxel 59-68 erb-b2 receptor tyrosine kinase 2 Homo sapiens 260-263 12173324-5 2002 The authors report the results of HER-2 screening from a Phase II trial of chemotherapy with trastuzumab and docetaxel in patients with HER-2-overexpressing prostate carcinoma. Docetaxel 109-118 erb-b2 receptor tyrosine kinase 2 Homo sapiens 136-141 9572489-3 1998 Higher expression of p185c-erbB2 in these breast cancer cell lines indeed correlated well with resistance to Taxol and Taxotere, and the degree of resistance was about 100-fold that in c-erbB2-overexpressing 435.eB transfectants, demonstrating that these breast cancer cells are highly resistant to Taxol. Docetaxel 119-127 erb-b2 receptor tyrosine kinase 2 Homo sapiens 21-32 11919237-0 2002 Phase II study of weekly docetaxel and trastuzumab for patients with HER-2-overexpressing metastatic breast cancer. Docetaxel 25-34 erb-b2 receptor tyrosine kinase 2 Homo sapiens 69-74 11919237-1 2002 PURPOSE: To evaluate the safety and efficacy of weekly docetaxel plus trastuzumab in women with HER-2-overexpressing metastatic breast cancer. Docetaxel 55-64 erb-b2 receptor tyrosine kinase 2 Homo sapiens 96-101 11919237-14 2002 CONCLUSION: Weekly docetaxel and trastuzumab is an active combination for treating patients with HER-2-overexpressing metastatic breast cancer. Docetaxel 19-28 erb-b2 receptor tyrosine kinase 2 Homo sapiens 97-102 11694787-7 2001 Preliminary results from a phase II study of Herceptin plus docetaxel in patients with HER2-overexpressing tumors indicate significant activity, with a response observed in 7 (44%) of 16 evaluable patients. Docetaxel 60-69 erb-b2 receptor tyrosine kinase 2 Homo sapiens 87-91 11778270-6 2000 E1A could sensitize HER2/neu-overexpressing human breast cancer cells to Taxotere by repressing HER2/neu expression. Docetaxel 73-81 erb-b2 receptor tyrosine kinase 2 Homo sapiens 20-24 11778270-6 2000 E1A could sensitize HER2/neu-overexpressing human breast cancer cells to Taxotere by repressing HER2/neu expression. Docetaxel 73-81 erb-b2 receptor tyrosine kinase 2 Homo sapiens 25-28 11778270-6 2000 E1A could sensitize HER2/neu-overexpressing human breast cancer cells to Taxotere by repressing HER2/neu expression. Docetaxel 73-81 erb-b2 receptor tyrosine kinase 2 Homo sapiens 96-100 11778270-6 2000 E1A could sensitize HER2/neu-overexpressing human breast cancer cells to Taxotere by repressing HER2/neu expression. Docetaxel 73-81 erb-b2 receptor tyrosine kinase 2 Homo sapiens 101-104 11872346-3 2002 The purpose of this study was to assess whether c-erbB-2 expression is associated with clinical sensitivity to docetaxel (T) or sequential methotrexate and 5-fluorouracil (MF). Docetaxel 111-120 erb-b2 receptor tyrosine kinase 2 Homo sapiens 48-56 11899413-13 2001 Currently, several combinations of platinum compounds (either cisplatin or carboplatin) with docetaxel and trastuzumab are under clinical testing in patients with MBC who overexpress HER2/neu. Docetaxel 93-102 erb-b2 receptor tyrosine kinase 2 Homo sapiens 188-191 11685733-2 2001 A phase I study was designed to evaluate docetaxel/estramustine plus trastuzumab, a humanized monoclonal antibody that binds to the HER2 receptor, in patients with metastatic androgen-independent prostate cancer (AIPC). Docetaxel 41-50 erb-b2 receptor tyrosine kinase 2 Homo sapiens 132-136 11521725-4 2001 A further phase II study is underway to investigate the combination of trastuzumab plus docetaxel in 30 HER2-positive patients with metastatic breast cancer. Docetaxel 88-97 erb-b2 receptor tyrosine kinase 2 Homo sapiens 104-108 10810934-0 2000 Docetaxel (Taxotere) in HER-2-positive patients and in combination with trastuzumab (Herceptin). Docetaxel 0-9 erb-b2 receptor tyrosine kinase 2 Homo sapiens 24-29 10810934-0 2000 Docetaxel (Taxotere) in HER-2-positive patients and in combination with trastuzumab (Herceptin). Docetaxel 11-19 erb-b2 receptor tyrosine kinase 2 Homo sapiens 24-29 10699953-4 2000 While MCF-10A Ha-ras cells showed an increased sensitivity, MCF-10A c-erbB-2 and MCF-10A HE cells exhibited a relative resistance to taxol and taxotere, with an approximately 3.5- to 6.5-fold higher IC(50) as compared with MCF-10A cells suggesting that c-erbB-2 overexpression has a dominant effect compared with an activated c-Ha-ras gene. Docetaxel 143-151 erb-b2 receptor tyrosine kinase 2 Homo sapiens 68-76 10699953-8 2000 Treatment with this agent, but not with a control scramble sequence, was able to overcome the effect of c-erbB-2 overexpression on MCF-10A cell sensitivity to taxol and taxotere, with a 20- to 40-fold shift in the IC(50) values for the 2 drugs. Docetaxel 169-177 erb-b2 receptor tyrosine kinase 2 Homo sapiens 104-112 9572489-3 1998 Higher expression of p185c-erbB2 in these breast cancer cell lines indeed correlated well with resistance to Taxol and Taxotere, and the degree of resistance was about 100-fold that in c-erbB2-overexpressing 435.eB transfectants, demonstrating that these breast cancer cells are highly resistant to Taxol. Docetaxel 119-127 erb-b2 receptor tyrosine kinase 2 Homo sapiens 25-32 34737636-0 2021 Analysis of the Effect of Trastuzumab Combined with Docetaxel on Serum Tumor Markers in the Treatment of HER-2 Positive Breast Cancer and Factors Influencing Therapeutic Efficacy. Docetaxel 52-61 erb-b2 receptor tyrosine kinase 2 Homo sapiens 105-110 33818899-0 2021 Tumor growth inhibition modeling of individual lesion dynamics and inter-organ variability in HER2-negative breast cancer patients treated with docetaxel. Docetaxel 144-153 erb-b2 receptor tyrosine kinase 2 Homo sapiens 94-98 33818899-3 2021 Herein, a tumor growth inhibition model was developed for describing the individual lesion time-course data from 183 metastatic HER2-negative breast cancer patients receiving docetaxel. Docetaxel 175-184 erb-b2 receptor tyrosine kinase 2 Homo sapiens 128-132 34948097-1 2021 The combination of trastuzumab plus pertuzumab plus docetaxel as a first-line therapy in patients with HER2-positive metastatic breast cancer has provided significant clinical benefits compared to trastuzumab plus docetaxel alone. Docetaxel 52-61 erb-b2 receptor tyrosine kinase 2 Homo sapiens 103-107 34872264-1 2021 BACKGROUND: This study sought to evaluate the cost-effectiveness of a pertuzumab, trastuzumab, and docetaxel (PTD) regimen and a trastuzumab and docetaxel (TD) regimen in the first-line treatment of human epidermal growth factor receptor 2 (HER2)-positive metastatic breast cancer (MBC) in the context of the Chinese health system. Docetaxel 99-108 erb-b2 receptor tyrosine kinase 2 Homo sapiens 205-239 34872264-1 2021 BACKGROUND: This study sought to evaluate the cost-effectiveness of a pertuzumab, trastuzumab, and docetaxel (PTD) regimen and a trastuzumab and docetaxel (TD) regimen in the first-line treatment of human epidermal growth factor receptor 2 (HER2)-positive metastatic breast cancer (MBC) in the context of the Chinese health system. Docetaxel 145-154 erb-b2 receptor tyrosine kinase 2 Homo sapiens 205-239 34872264-1 2021 BACKGROUND: This study sought to evaluate the cost-effectiveness of a pertuzumab, trastuzumab, and docetaxel (PTD) regimen and a trastuzumab and docetaxel (TD) regimen in the first-line treatment of human epidermal growth factor receptor 2 (HER2)-positive metastatic breast cancer (MBC) in the context of the Chinese health system. Docetaxel 145-154 erb-b2 receptor tyrosine kinase 2 Homo sapiens 241-245 9285690-1 1997 Breast cancer cells that overexpress HER-2/neu are more resistant to chemotherapeutic agents such as paclitaxel (Taxol) and docetaxel (Taxotere) than those that do not overexpress HER-2/neu. Docetaxel 124-133 erb-b2 receptor tyrosine kinase 2 Homo sapiens 37-46 9285690-1 1997 Breast cancer cells that overexpress HER-2/neu are more resistant to chemotherapeutic agents such as paclitaxel (Taxol) and docetaxel (Taxotere) than those that do not overexpress HER-2/neu. Docetaxel 135-143 erb-b2 receptor tyrosine kinase 2 Homo sapiens 37-46 34533681-1 2021 BACKGROUND: Docetaxel, carboplatin and trastuzumab, with or without pertuzumab (TCH(P)), has become the preferred (neo)adjuvant regimen for HER2-positive breast cancer. Docetaxel 12-21 erb-b2 receptor tyrosine kinase 2 Homo sapiens 140-144 34706686-1 2021 BACKGROUND: Docetaxel in combination with two HER2-directed therapies, trastuzumab and pertuzumab, is the current standard frontline therapy for patients with metastatic HER2-positive breast cancer. Docetaxel 12-21 erb-b2 receptor tyrosine kinase 2 Homo sapiens 46-50 34706686-1 2021 BACKGROUND: Docetaxel in combination with two HER2-directed therapies, trastuzumab and pertuzumab, is the current standard frontline therapy for patients with metastatic HER2-positive breast cancer. Docetaxel 12-21 erb-b2 receptor tyrosine kinase 2 Homo sapiens 170-174 34737636-1 2021 Objective: To explore the influence of trastuzumab (TZ) combined with docetaxel (DTX) on serum tumor markers (TMs) in the treatment of human epidermal growth factor receptor 2-positive (HER-2+) breast cancer (BC) and to analyze the factors influencing therapeutic efficacy. Docetaxel 70-79 erb-b2 receptor tyrosine kinase 2 Homo sapiens 141-175 34737636-1 2021 Objective: To explore the influence of trastuzumab (TZ) combined with docetaxel (DTX) on serum tumor markers (TMs) in the treatment of human epidermal growth factor receptor 2-positive (HER-2+) breast cancer (BC) and to analyze the factors influencing therapeutic efficacy. Docetaxel 70-79 erb-b2 receptor tyrosine kinase 2 Homo sapiens 186-191 34737636-1 2021 Objective: To explore the influence of trastuzumab (TZ) combined with docetaxel (DTX) on serum tumor markers (TMs) in the treatment of human epidermal growth factor receptor 2-positive (HER-2+) breast cancer (BC) and to analyze the factors influencing therapeutic efficacy. Docetaxel 81-84 erb-b2 receptor tyrosine kinase 2 Homo sapiens 141-175 34737636-1 2021 Objective: To explore the influence of trastuzumab (TZ) combined with docetaxel (DTX) on serum tumor markers (TMs) in the treatment of human epidermal growth factor receptor 2-positive (HER-2+) breast cancer (BC) and to analyze the factors influencing therapeutic efficacy. Docetaxel 81-84 erb-b2 receptor tyrosine kinase 2 Homo sapiens 186-191 34737636-12 2021 Conclusion: TZ+DTX can effectively improve the clinical efficacy of HER-2+ BC patients and reduce their levels of serum TMs and IFs. Docetaxel 15-18 erb-b2 receptor tyrosine kinase 2 Homo sapiens 68-73 34215870-0 2021 A randomized phase III study comparing trastuzumab emtansine with trastuzumab, pertuzumab and docetaxel in elderly patients with advanced stage HER2-positive breast cancer: Japan Clinical Oncollgy Group Study (JCOG1607, HERB TEA study). Docetaxel 94-103 erb-b2 receptor tyrosine kinase 2 Homo sapiens 144-148 34165503-2 2021 Objective: To assess pathologic complete response (pCR) to standard neoadjuvant therapy of combination docetaxel, trastuzumab, and pertuzumab (DTP) vs T-DM1 monotherapy in patients with ERBB2 (formerly HER2)-positive breast cancer. Docetaxel 103-112 erb-b2 receptor tyrosine kinase 2 Homo sapiens 186-191 34165503-2 2021 Objective: To assess pathologic complete response (pCR) to standard neoadjuvant therapy of combination docetaxel, trastuzumab, and pertuzumab (DTP) vs T-DM1 monotherapy in patients with ERBB2 (formerly HER2)-positive breast cancer. Docetaxel 103-112 erb-b2 receptor tyrosine kinase 2 Homo sapiens 202-206 34224826-1 2021 BACKGROUND: The phase III CLEOPATRA trial established the combination of pertuzumab, trastuzumab and docetaxel as standard first-line therapy for HER2-positive locally recurrent/metastatic breast cancer (LR/mBC). Docetaxel 101-110 erb-b2 receptor tyrosine kinase 2 Homo sapiens 146-150 34313026-0 2021 Multistate model for pharmacometric analyses of overall survival in HER2-negative breast cancer patients treated with docetaxel. Docetaxel 118-127 erb-b2 receptor tyrosine kinase 2 Homo sapiens 68-72 34533811-8 2021 CONCLUSIONS: Both for patients with HER2-positive and negative metastatic breast cancer, docetaxel and bevacizumab with or without trastuzumab as first-line treatment resulted in long survival, especially in terms of progression-free survival. Docetaxel 89-98 erb-b2 receptor tyrosine kinase 2 Homo sapiens 36-40 34296283-0 2021 Corrigendum to: A randomized phase III study comparing trastuzumab emtansine with trastuzumab, pertuzumab and docetaxel in elderly patients with advanced stage HER2-positive breast cancer: Japan Clinical Oncology Group Study (JCOG1607, HERB TEA study). Docetaxel 110-119 erb-b2 receptor tyrosine kinase 2 Homo sapiens 160-164 35073148-0 2022 Combination of Trastuzumab, Pertuzumab, and Docetaxel in Patients With Advanced Non-Small-Cell Lung Cancer Harboring HER2 Mutations: Results From the IFCT-1703 R2D2 Trial. Docetaxel 44-53 erb-b2 receptor tyrosine kinase 2 Homo sapiens 117-121 34352937-0 2021 Tumor-infiltrating Lymphocytes in Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer Receiving Neoadjuvant Docetaxel, Carboplatin, Trastuzumab, and Pertuzumab. Docetaxel 120-129 erb-b2 receptor tyrosine kinase 2 Homo sapiens 40-74 34150608-12 2021 Conclusions: Our data provide evidence that the emergence of CTC-WBC clusters underwent EMT before treatment is associated with significantly poorer PFS in HR-positive/HER2-negative metastatic breast cancer patients receiving docetaxel plus capecitabine, which may be used as a parameter to predict the clinical outcomes and a potential target for individualized therapy. Docetaxel 226-235 erb-b2 receptor tyrosine kinase 2 Homo sapiens 168-172 34268925-0 2021 Cardiac safety of neoadjuvant chemotherapy with epirubicin and cyclophosphamide followed by docetaxel/pertuzumab/trastuzumab for HER2-positive breast cancer patients. Docetaxel 92-101 erb-b2 receptor tyrosine kinase 2 Homo sapiens 129-133 35073148-3 2022 We prospectively evaluated the effectiveness of the combination of two antibodies against human epidermal growth factor 2 (HER2 (HER2) trastuzumab and pertuzumab with docetaxel; trastuzumab and pertuzumab) and docetaxel. Docetaxel 167-176 erb-b2 receptor tyrosine kinase 2 Homo sapiens 123-127 35073148-3 2022 We prospectively evaluated the effectiveness of the combination of two antibodies against human epidermal growth factor 2 (HER2 (HER2) trastuzumab and pertuzumab with docetaxel; trastuzumab and pertuzumab) and docetaxel. Docetaxel 210-219 erb-b2 receptor tyrosine kinase 2 Homo sapiens 123-127 35083840-1 2022 The first-line treatment of advanced and metastatic human epidermal growth factor receptor type 2 (HER2+) breast cancer requires two HER2-targeting antibodies (trastuzumab and pertuzumab) and a taxane (docetaxel or paclitaxel). Docetaxel 202-211 erb-b2 receptor tyrosine kinase 2 Homo sapiens 99-103 35083840-1 2022 The first-line treatment of advanced and metastatic human epidermal growth factor receptor type 2 (HER2+) breast cancer requires two HER2-targeting antibodies (trastuzumab and pertuzumab) and a taxane (docetaxel or paclitaxel). Docetaxel 202-211 erb-b2 receptor tyrosine kinase 2 Homo sapiens 133-137 35083840-3 2022 To replace this regimen, reduce infusion time, and enhance efficacy, a single therapeutic is developed based on trastuzumab-conjugated nanoparticles for co-delivering docetaxel and siRNA against HER2 (siHER2). Docetaxel 167-176 erb-b2 receptor tyrosine kinase 2 Homo sapiens 195-199 35113748-5 2022 CONCLUSIONS: We propose that trastuzumab, pertuzumab, and docetaxel suppress HER2 and Ki67 in the cornea and lacrimal gland. Docetaxel 58-67 erb-b2 receptor tyrosine kinase 2 Homo sapiens 77-81 35113748-2 2022 CASE DESCRIPTION: A patient, diagnosed with metastatic breast cancer and positive for human epidermal growth factor receptor 2 (HER2) with high Ki67, presented with bilateral severe marginal corneal infiltration upon undergoing first cycle of triple chemotherapy: trastuzumab, pertuzumab, and docetaxel. Docetaxel 293-302 erb-b2 receptor tyrosine kinase 2 Homo sapiens 92-126 35113748-2 2022 CASE DESCRIPTION: A patient, diagnosed with metastatic breast cancer and positive for human epidermal growth factor receptor 2 (HER2) with high Ki67, presented with bilateral severe marginal corneal infiltration upon undergoing first cycle of triple chemotherapy: trastuzumab, pertuzumab, and docetaxel. Docetaxel 293-302 erb-b2 receptor tyrosine kinase 2 Homo sapiens 128-132 35038825-0 2022 Real-World Evidence of Trastuzumab, Pertuzumab, and Docetaxel Combination as a First-Line Treatment for Korean Patients with HER2-Positive Metastatic Breast Cancer. Docetaxel 52-61 erb-b2 receptor tyrosine kinase 2 Homo sapiens 125-129 35008143-1 2022 Purpose: Docetaxel/carboplatin/trastuzumab/pertuzumab(TCHP) regimen is frequently used to treat early and locally advanced human epidermal growth factor receptor 2(HER2)-positive breast cancer(BC) in neoadjuvant setting. Docetaxel 9-18 erb-b2 receptor tyrosine kinase 2 Homo sapiens 129-163 35008143-1 2022 Purpose: Docetaxel/carboplatin/trastuzumab/pertuzumab(TCHP) regimen is frequently used to treat early and locally advanced human epidermal growth factor receptor 2(HER2)-positive breast cancer(BC) in neoadjuvant setting. Docetaxel 9-18 erb-b2 receptor tyrosine kinase 2 Homo sapiens 164-168